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1. Abstract 
 
Increasing bacterial drug resistance and the emergence of dangerous resistant pathogens like 
methicillin-resistant Staphylococcus aureus is driving an urgent need to develop new 
antibiotics. Antimicrobial peptides (AMPs) and metals are two classes of antibacterial agents 
being explored as novel therapeutics. AMPs are produced as a part of innate immune system 
of living organisms and have broad spectrum activity and a bactericidal effect making bacteria 
less able to develop resistance., Metals are one of the oldest antibacterial agents known to 
humans. Notably, silver is very effective, and although its exact mode of action/s is unclear its 
ability to bind to a variety of enzymes is likely important.   This project aims to investigate 
whether the coordination of silver to AMPs can create a synergistic antibacterial agent. To 
achieve this, AMPs, based on their potential to bind Ag(I), were selected from large AMP 
databases available online. Three AMPs, latarcin 3b, pleurain R1, tigerinin1, were selected. 
Further two Ag(I)-binding neuropeptides having properties consistent with antibacterial 
activity were also investigated. These were the tachykinins Neurokinin B, Substance P. Finally, 
Substance P was modified to include a methionine at its N-terminus (M1 Substance P) to 
generate a predicted high-affinity Ag(I)-binding site.  The physiochemical properties of all the 
peptides were assessed using the R computational tool and these were related to potential 
antibacterial potential. Neurokinin B and Substance P have previously been shown to bind 
Ag(I), and the ability of the remaining peptides to coordinate Ag(I) was assessed using NMR 
and electronic spectroscopy. All but pleurain R1 and tigerinin1 could coordinate Ag(I), and 
further investigation of pleurain indicated that the lack of Ag(I)-binding was due to disulphide-
bond formation. The Peptide-Ag(I) complexes were then studied for their antibacterial 
properties against gram negative bacteria using percentage inhibition and time-kill analysis. 
The results of this analysis showed that two complexes, latarcin 3b-Ag(I), and M1SP-Ag(I) 
displayed synergistic activity. Finally, the cellular location of silver after cultures were treated 
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with these complexes was determined. These results show that silver alone is located mainly 
in the periplasm, but coordination to the peptides traps the metal in the membrane. This 
suggests that the synergistic effect is due to improved membrane-lytic activity. It can be 
concluded that the Peptide-Ag(I) complex can hold potential as next-generation antibacterial 
agents. 
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2. Introduction 
 
Every living organism undergoes characteristic change over successive generations; when a 
microorganism becomes unresponsive towards a drug, to which it was earlier susceptible, it is 
said to have become resistant. This phenomenon of a microorganism to evolve and become 
resistant to microbial drugs is called antimicrobial resistance (AMR). A bacteria is known to 
develop resistance to antibiotics by undergoing mutations and structural modifications 
including loss of antibiotic binding sites and loss of porins that leads to deactivation, 
dysfunction or elimination of antibiotics from the bacterial cell (1,2).  
 
The phenomenon of microbial resistance has been known to exist since the development of 
antibiotics in the 1920s (3,4). Since then, excessive consumption and misuse of antibiotics has 
triggered the natural process of antimicrobial resistance. Studies have shown that since the first 
time Penicillin was used 50% of hospital Staphylococcus aureus isolates have become resistant. 
Between 1930 and 1960 about 20 classes of new antibiotics were introduced that remained 
effective for 50 years. By the end of 2004, 70% of the bacteria became resistant to at least one 
of the antibiotics that was in use (5). If this pattern repeats itself, then to survive for the next 
50 years we would need the development of at least 20 novel classes of antibiotics. 
 
Being trapped in this vicious cycle of evolution there is a need for a constant supply of novel 
classes of antibiotics to stay a step ahead of AMR. Unfortunately, the production and 
development of new antibiotics has reached a record low in the last few years (6). As the stock 
of effective antibiotics is exhausting, we are approaching the ‘pre-antibiotic’ era which could 
be a serious threat to mankind. There might be a situation where a scratch could be fatal and 
surgery become impossible. This is evident with the emergence of new pathogens, like SARS 
virus in 2003 and H1N1 influenza in 2009 (7). The need of new antibiotics increases with the 
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emergence of newer pathogens. A report from the United Kingdom government suggests that 
AMR could be a reason for the death of over 300 million people by 2050 and could cost a 
financial loss of up to 100 trillion dollars (8). Thus, the need is to create new drugs and not just 
preserve the existing ones. 
 
Most of the existing antibiotics have a single mode of action and are therefore vulnerable to 
the development of antibiotic resistance in a relatively short period of time. They are primarily 
bacteriostatic in nature so they limit the growth of bacteria but fail to kill it (9). About 90% of 
the drugs approved in the last decade are either modified versions of the existing antibiotics or 
are  derivatives of the existing antibiotic classes (10). These new forms are improved and more 
effective, but their mechanism of action is similar to the existing antibiotics where they target 
cell wall synthesis, bacterial protein synthesis, bacterial DNA duplication or folate synthesis. 
Since they share a lot of similarities with conventional antibiotics, they are suspected to soon 
become resistant. Hence, the answer is development and exploration of newer strategies in 
antibacterial drug discovery by exploring unconventional sources and targets to develop new 
and target-specific antibacterial agents. 
 
The conventional concept of screening for novel antibacterial agents has primarily involved 
exposure of whole cells or purified proteins to arrayed collections of small molecules. While 
these approaches were remarkably successful in early discovery efforts, it is becoming apparent that 
such methods are unlikely to meet the future needs of drug development for infectious disease. 
In recent years, basic advances at the interface of biology and chemistry and growing 
knowledge of bacterial physiology have built an exceptional foundation that can be leveraged 
in the search for new therapeutics. Acknowledging the need for novel sources, the primary 
objective of this project is to explore the potential of peptide-metal complexes as antibacterial 
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agents. Some peptides are naturally antimicrobial, as are some metals, and by linking the two 
together we may find enhanced activity against resistant bacterial strains. 
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3. Literature Review 
 
 Bacterial Resistance 
 
Bacteria are known to develop resistance in three different ways. First is the intrinsic resistance, 
it is the normal defence mechanism of a bacteria. Second, acquired resistance, the bacteria 
acquire resistance due to external force leading to mutations. Third, genetic change, the bacteria 
alter its genome to survive the impact of antibiotics. 
 
Intrinsic resistance is a phenomenon that occurs to bacteria which is a biological response to 
environment. For example, Penicillin that attacks the cell wall is ineffective against the bacteria 
that does not have a cell wall. By the help of medical advancements and genome analysis 
technique it has been revealed that various bacteria contain genes that result in varied 
phenotypical response to antibiotics that cause resistance. Some of the phenotypic responses 
could be inability of a drug to bind to the target, the inaccessibility of the drug to the bacteria, 
the production of enzymes for drug inactivation and the presence of genetically coded exporters 
that extrude the drug. 
 
Acquired resistance is the phenomenon where the bacteria modify itself to survive in the 
unfavourable environment produced by antibiotics. Acquired resistance, unlike intrinsic 
resistance, is adopted by or is prevalent in some strains of a particular species. Primarily, 
bacteria develop resistance by attaining an antibiotic-resistant gene from external sources via 
transformation, transduction or conjugation. The process of simple mating is called 
conjugation, in which bacteria transfers a gene encoding resistance to antibiotics to another 
bacterium. Transduction is the transfer of resistant gene from one bacteria to another by the 
help of bacteriophages. Another ability that bacteria exhibit is to acquire free DNA floating in 
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the environment. A dangerous situation arises when the bacteria acquires resistance through 
multiple mechanisms leading to broad spectrum resistance.  
 
The third technique of genetic change or mutation, is a rare and a spontaneous mechanism by 
which bacteria modifies its DNA to develop resistance against antibiotics. Mutation is a natural 
and a very slow way of developing resistance. One in a million bacteria undergoes a single 
base pair modification in its DNA that leads to a complete change in the functioning of the 
bacteria by target site modification, developing strong antibiotic efflux, or releasing drug 
inactivating enzymes. Once a mutation occurs, these bacteria reproduces and spreads in the 
population. When these bacteria adopt more than one mechanism of resistance the treatments 
against these bacteria becomes more challenging and complex. 
 
 Gram-negative Bacteria 
 
With emerging resistance amongst some deadly bacteria, there is a growing need to develop 
antibacterial drugs that not only kill the resistant pathogen, but also prevent them from 
developing further resistance (11). The resistance is more prevalent in gram negative bacteria 
as they have multiple protective layers including a thick lipopolysaccharide cell wall (12,13) . 
Additionally,  gram negative bacteria develop resistance faster than gram positive bacteria 
because of mobile genes on the plasmids that readily spread through bacterial populations (14). 
Gram negative bacteria develop resistance in multiple ways; they can exhibit intrinsic 
resistance by inactivating antibiotics by releasing certain enzymes or by flushing out 
antibacterial agents through efflux pumps. Target site modification and loss of porins which 
restricts the passage of antibiotics though the cell membrane are some other mechanisms 
causing resistance (15). Hence, this study uses gram negative bacteria to study the antibacterial 
effect of peptides and peptide-metal conjugates. 
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3.2.1. Pseudomonas aeruginosa  
 
Pseudomonas aeruginosa (P. aeruginosa) is a common gram-negative bacterium responsible 
for causing chronic lung infections. It is an opportunistic bacteria and attacks people with 
compromised immune system, particularly patients with cystic fibrosis. This rod shaped 
bacteria is one of the few lethal bacteria that exhibit multiple drug resistance and might develop 
total drug resistance in the future (16). P. aeruginosa are non-spore forming motile rods, 
oxidase positive and non-fermenters. These organisms under different conditions secrete 
various pigments that gives them a distinct colour – for instance, pyorubin gives it a red-brown 
colour, pyocanin gives blue-green and pyoverdine gives yellow-green colour (17). P. 
aeruginosa  exhibit all the resistance mechanism possessed by gram negative bacteria, but three 
mechanisms that dominate are the production of β-lactamases, loss of porins and upregulation 
of efflux pumps (18). P. aeruginosa possesses a gene that regulates the production of β-
lactamases enzyme. This enzyme provides resistance against common antibiotics like 
penicillin, cephalosporin and cephamycin. In the case of over production it may even show 
resistance against carbapenems (19). Porins are small molecules that form channels through 
the cellular membrane. P. aeruginosa uses porins to release β-lactamases enzyme in the outer 
membrane. It produces multiple porins such as Oprf, oprD. Some of the antibiotics target P. 
aeruginosa  by entering the cell through these porins, thus as a defence mechanism, P. 
aeruginosa  loses these porins which blocks the pathway for antibiotics like imipenem (20). 
Another defence mechanism adopted by P. aeruginosa involves the use of efflux pumps. P. 
aeruginosa is known to have four efflux system, mexAB-oprM, mexXY-oprM, mexCD-oprJ 
and mexEF-oprN. Each system involves the participation of a pump in the cytoplasmic 
membrane, a porin in the outer membrane and a linker protein to connect the two. This system 
works in sync to pump out the antibiotics like carbapenems, quinolones and aminoglycosides 
(21). Other common factors for P. aeruginosa ’s to develop resistance include low cell wall 
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permeability, a strong gene regulatory system that produces various defence enzymes and 
molecules. It also has the ability to acquire additional genes from other organisms to strengthen 
its defence system (19).  
3.2.2. Escherichia coli 
 
E. coli is one of the most studied free-living gram negative organism with more than seven 
hundred known serotypes (22). Most of the E. coli are not infectious and are also found in the 
gut of organisms but some of them can cause gastrointestinal and urinary tract infections (23). 
The rod shaped motile bacteria is a facultative anaerobe that grows optimally at 37oC (24). 
Studies report that multidrug resistant E. coli depends primarily on  efflux to remove  
antibiotics from the cell (25). Efflux based resistance was first detected in E. coli against 
Tetracycline during the 1970’s (26). However, it is not the dominating defence mechanism in 
E. coli (27). E. coli shows resistance against antibiotics by quinolone resistance, upregulation 
of β-lactamases, alteration of genes and loss of porins.   
There are two mechanisms underlying quinolone resistance, first is by reducing cell 
permeability or enhancing efflux and second by alteration of proteins involved in DNA 
replication including topoisomerase and DNA gyrase. E. coli upregulates the production of β-
lactamases that inactivates the antibiotic. Many of the antibiotics bind to genes to cause 
inactivation. E. coli has the ability to alter its genes to prevents the antibiotic binding or it may 
entirely eliminate the binding site for the antibiotic. Similar to P. aeruginosa, E. coli has the 
ability to lose some of its porins that prevent the entering of the antibiotic into the cell. Removal 
of OmpF porin is responsible for the resistance against kanamycin (28). 
 
 Antimicrobial Peptides 
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Antimicrobial Peptides (AMPs) are present in all living organisms in varieties and abundance. 
They are oligopeptides, generally containing between 5 and 50 amino acids (29). These are low 
molecular weight and exhibit broad spectrum antimicrobial activity against bacteria, fungi, 
virus and protozoa (30).  One of the most distinctive features of an AMP is its structure, like 
most proteins they can have regular secondary structure elements (e.g. α-helix, β-sheet) or they 
may be unstructured. Often, many short peptides are unstructured until they interact with other 
proteins or lipids. The antibacterial activity of an AMP is largely governed by its structure. 
Most of the AMPs are positively charged and exhibit an amphipathic structure i.e. they have 
distinctly different hydrophobic and hydrophilic regions. This structure makes them soluble in 
both aqueous and non-aqueous states thus enabling them to show an antibacterial effect by 
penetrating through the lipopolysaccharide layer of cell membrane. This causes membrane 
disintegration and also allows the peptide to interact with and damage cytosolic component 
(31). Hence, AMPs often have multiple modes of action. Another unique feature of AMPs is 
that sometimes they form their active structure after coming in contact with their target. This 
property of AMPs make it harder to predict their mechanism of action against the bacteria (32). 
 
Even though their exact mechanism of action is difficult to predict, some of their mechanisms 
have been reported in literature. The broad action mechanism of AMPs is because of the 
multiple targets it hits within the cell (33). The unique structure and amphipathic nature of 
AMPs facilitate their direct interaction with the cytoplasmic membrane of both gram-positive 
and gram-negative bacteria and also eukaryotic microorganisms (34). AMPs can cause damage 
to a bacterial cell in various ways including causing membrane barrier disruption, negatively 
altering cytoplasmic membrane permeability, and prevention of protein synthesis, cell division, 
cell wall biosynthesis and macromolecular biosynthesis. This makes it difficult for a bacterium 
to develop resistance. For example, when P. aeruginosa was exposed to gentamycin for 30 
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passages it developed resistance by 190-fold. In contrast, after exposure to AMPS the resistance 
was only 2-4 fold (35). Defensins and cathelicidins are two principal classes of AMPs that have 
been identified in mammals which show a broad range of antimicrobial activity against bacteria 
that have demonstrated resistance to antibiotic treatment. Human β-defensin 3 (HBD3) 
possesses bactericidal activity against many potentially pathogenic microbes, such as 
multidrug-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium 
(36). On the other hand, cathelicidins exert antibacterial activity against both gram-positive 
and gram-negative bacteria via electrostatic interactions with the bacterial cell membrane (37). 
 
3.3.1. Mechanism of Action 
 
3.3.1.1. Extracellular mechanisms 
 
The primary  mechanism of action of AMPs is the bacterial cell membrane disintegration. 
There are three ways in which the AMPs can disintegrate the membrane (Figure. 1)  
1) By forming a toroidal pore: In this the peptide binds to the membrane followed by 
aggregation which causes the inner and outer lipid moieties to fold inwards forming a pore 
lined by peptide units causing the lipid membrane to tightly bind with it (38). Some of the 
peptides that show this activity are melittin, lacticin Q and magainin 2 (39,40). 
2) The barrel starve model or the helical bundle model: the peptide units arrange themselves 
parallel to the phospholipid molecules of the membrane. The orientation is such that the 
hydrophilic part of the peptide lines with the transmembrane channel and the hydrophobic 
part binds to the lipid moieties. This causes the cytoplasmic contents to leak out which leads 
to the death of the cell. Some of the examples are almathecin, gramicidin S (41,42). 
3) The carpet model: Unlike the two models described above, in this the peptides do not 
interact with the membrane. They accumulate on the outer membrane surface and exert 
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pressure on the cell causing the cell to disrupt by destroying membrane electrostatics (43). 
Cecrophin P1 operates with such mechanism (44). 
 
 
Figure 1: Represents the extracellular mechanism of action of antimicrobial peptides. The AMP 
acts on the membrane in three ways, A. Toroidal pore, B. Barrel- starve model, C. Carpet mode. 
 
3.3.1.2. Intracellular mechanism 
 
After penetrating the cell membrane, AMPs interact with the intracellular components of a cell. 
AMPs due to their small size have a higher ability to traverse the cellular membrane as 
compared to larger proteins and immune cells, which enables them to generate immediate 
defence response against the pathogen (45). The peptide generally enters the membrane using 
lipid assisted or receptor mediated membrane translocation. Histatins (46) and bac7 (47) are 
two of the commonly studied peptides for such mechanism. The most commonly reported 
intracellular mechanism is the nucleic acid and metabolic pathway inhibition. The positively 
charged AMPs bind to the negatively charged DNA/RNA in the cell and cause dysfunction. 
For example, indolocidin 2 targets the bacterial DNA where it binds to the topoisomerase 1 
that causes relaxation of the DNA (48), buforin 2 binds to both, the bacterial DNA and RNA 
without causing any membrane damage (49), and tachyplesin I binds to the minor groove of 
Navya Kapoor | 24  
 
the double stranded DNA and alters the structure, normal transcription and replication 
processes  (50). 
 
Apart from nucleic acid, some of the peptides bind to lipid targets inside the cell.  The AMP 
Nisin targets lipid moieties in the cell and prevents it from converting to peptidoglycan thus 
Nisin prevents  cell wall synthesis (51,52). Furthermore, several peptides have been reported 
to target the bacterial proteins especially the proteins involved in metabolic processes of the 
cell (51).  They bind to the DNA replication enzymes preventing the bacteria from replication 
example, cecrophin (44). 
 
 Advantages of AMPs over Antibiotics 
 
Antimicrobial peptides are a part of the innate immune system in every organism. They do this 
by, firstly, increasing the immunity by increasing the production and release of chemokine 
through immune and epithelial cells. Secondly, by boosting angiogenesis and wound healing, 
thirdly by wielding pro-apoptotic and anti-apoptotic effects on immune cells and, lastly, by 
acting as adjuvants to promote adaptive immunity and reduce inflammatory responses (53,54). 
Conventional antibiotics have no such response on the host’s immune system and instead they 
may cause over-reaction of the immune system (55). 
 
AMPs, as a part of their action, not only show a direct antimicrobial activity of cell rupturing, 
but they also interfere with the biological machinery of a microorganism to prevent the 
synthesis and normal metabolic functioning of macromolecules (35). Other than that, AMPs 
are also known to suppress the formation and induce dissolution of biofilms (56). Due to their 
complex mechanism of action, it takes a longer time for bacteria to get around each mechanism 
and develop resistance against all the mechanisms. Even if the bacteria develop the ability 
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shield one effect, other mechanisms may still be able to mediate its killing. In contrast, 
antibiotics do not show multiple mechanism and it becomes easier for the bacteria to develop 
resistance against it. 
Most antibiotics are known to cause bacterial killing by inhibiting the cell wall synthesis or 
protein synthesis and, in rare cases, it may alter the bacterial cell membranes or inhibit the 
nucleic acid synthesis (9). Most antibiotics are bacteria specific in terms of their mechanism 
and even though they attack an important component for cell growth their single target makes 
them prone to becoming ineffective. The bacteria evolve to replace or remove that essential 
growth component making the antibiotic ineffective. On the other hand, the primary target of 
the AMPs is the bacterial cell membrane. Since cell membrane is an integral part of every 
microorganism, it is highly unlikely to be replaced or completely restructured. Thus, AMPs are 
effective against a large number of bacteria with a very low chance of becoming resistant (38). 
AMPs are less likely to gain resistance from bacteria due to three main reasons. First, the 
opposite charges on peptides and charged cellular membranes of the bacterial cell causes 
membrane permeability and rapid cell death. Second, AMPs have multiple mechanism of 
action against the bacteria that decreases the probability of the bacteria to develop resistance 
against it (57). As noted above, Nisin is a peptide known to have two main mechanism of action 
against bacteria (52). Third is that the AMP are modulators of innate immunity as the AMPs 
act as a part of the innate immunity system rather than acting directly on the bacteria. Thus, the 
likelihood of bacteria to develop resistance goes further down (58). 
 Metals as Antibacterial 
 
Metals have been used as antibacterials for centuries and unlike other known antibacterial 
agents, they are still effective and have no cases of reported resistance against them.  Metals 
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have a broad mechanism of action against various bacteria, especially gram-negative bacteria. 
Silver is one such metal that has been used for centuries for its antibacterial properties. Silver 
has been used as a germicide to keep the water potable for months by being used as coating 
inside water tanks in ships and bottles. (59). During the 1800s when Neisseria 
gonorrhoeae was discovered, aqueous silver nitrate drops were added to a newborn’s eyes as 
a prevention against gonorrhoea  (60).  
 
It is astonishing to know that no bacterial resistance has been reported against silver even 
though it has been used as an antibacterial for so long. This is possible because of the multiple 
mechanisms of silver. One of the most commonly studied mechanism of actions is the protein 
deactivation caused by silver binding to sulphur. Sulphur is an essential component in all living 
forms, and is present in vitamins, amino acids and proteins (cysteine and methionine) and also 
as inorganic sulphide (e.g. iron-sulphur clusters). Due to sulphurs abundance in living forms, 
silver binding to sulphur disrupts the normal functioning of cell leading to its death (61). Silver 
also binds to the thiol containing compounds in the cell membrane that are responsible for ion 
transport and energy. The binding of silver to thiol groups leads to enzyme deactivation 
resulting in a disrupted metabolic reaction. Thiols are required for the formation of disulphide 
bonds which are an important part of protein structure formation, stability and function. Thus, 
any alteration in the disulphide forms affects the normal functioning of a cell (62). In some 
papers silver has also been reported to bind to the bacterial DNA. It is proposed that silver 
enters between purine and pyrimidine and disrupts the hydrogen bonding between the two, 
denaturing the DNA of the bacteria. It also disrupts intracellular structures including 
ribosomes, and mitochondria (63). 
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On the contrary, in a recent study, Mulley et al. (64) reported that the presence of extracellular, 
endogenous glutathione and cysteine reduced the toxicity of silver against pathogenic bacteria 
by preventing it from cellular interactions. A similar study shows that in the presence of thiols 
silver showed reduced toxicity against P. aeruginosa  (65). Given these recent studies it is 
possible that the presence of an exogenous Ag(I)-binding peptide  may prevent silver from 
binding to the endogenous cysteine and glutathione and allow silver to interact with bacterial 
cells and exhibit bactericidal activity. Figure. 2 shows the proposed effect of exogenous 
peptide-Ag(I) binding on the antimicrobial activity. 
 
 
Figure 2. Proposed mechanism of action by combining peptide+ Ag to improve antibacterial 
activity of Silver. A) shows the binding of silver to extracellular cysteine and glutathione 
present in the cell b) in the presence of an AMP, silver is not bound to cysteine or glutathione 
and interacts with the bacterial cell. 
 
Another suggested mechanism states that the exposure to silver can lead to dehydration of the 
bacterial cell, although the mechanism for this is elusive (66). Silver can induce cell toxicity 
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and oxidative stress in the cells by the release of free radicals and reactive oxygen species and 
the metal may also be involved in tampering of signal transduction pathways. (67). 
 
Despite its numerous applications and strong antibacterial property, it cannot be directly used 
as a drug because of its high toxicity to prokaryotic and eukaryotic cells. The problem of 
toxicity may be resolved by combining these metals to antimicrobial peptides. Complexing the 
metal with peptides would result in a broader and a far more complex mechanism of action, 
which could have various advantages, such as: a) metal may provide structural stability to the 
peptides, b) metals may facilitate easier transportation of the peptide in the cell c) combination 
of two independent antibacterial agents could show a synergistic effect and overcome the 
problem of toxicity. d)  killing time may also be considerably reduced (68).  
 
 Neuropeptides as Antimicrobials 
 
Antimicrobial peptides are known to be predominantly present in the host-environment 
interfaces such as oral cavity, respiratory tract and the gastro intestinal tract which are largely 
the portals of microbial entry into the host. Similar to AMPs, neuropeptides (NPs) are generally 
amphipathic molecules that permits them to interact in the aqueous phase between receptor and 
nerve ending and also within the target membrane (69). More recent data suggests that NPs can 
contribute to the innate defence mechanism against microorganisms (70). 
 
Neuropeptides in general are used to transmit and modulate signals in the central and peripheral 
neural system. Due to their short half-life of about 4-5 minutes in vivo, NPs have not gained a 
lot of attention as an antibacterial (71). Due to the slow mechanism of regeneration of NPs at 
the nerve endings, the concentration of NPs at nerve ending is not adequate to completely 
overcome or decrease the microbial load. However, the release of the NPs from the immune 
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cells suggest their function to be similar to the conventional host defence peptides which 
highlights a potential to have direct antimicrobial activity or immunomodulatory effect on the 
host cells. 
 
Neuropeptides and host defence peptides share similar structural and biophysical 
characteristics such as low molecular mass, cationicity and amphipathicity. These properties 
allow the peptides to interact with eukaryotic cell membranes and membrane bound receptors. 
It may also allow it to interact with the pathogen’s cell membrane leading to membrane 
disruption and possibly leading to cell death. The presence of large amounts of NPs in mucosal 
barriers of the gastrointestinal, genital and respiratory tracts and skin, which are common sites 
for microbial invasion, suggest a potential function as a host defence peptide (72). 
 
Various studies have reported direct antimicrobial, anti-fungal and anti-parasitic activities of 
antimicrobial peptides. Similar to AMPs, most of the NPs have membrane disruption as the 
predominant mechanism of action (32). The structural characteristics of NPs facilitate 
permeabilization of the membrane. Studies on Neuropeptide Y, α- Melanocyte-stimulating 
hormone (α-MSH) and adrenomedullin (AM) have confirmed the loss of microbial membrane 
integrity (73).  
 
Other suggested mechanisms of action of NPs include interference of NPs with intracellular 
functions such as mechanisms associated with membrane synthesis of the microbial cell. 
Interaction between metabolic targets and the peptide is another mode of attack against the 
pathogen. AM has shown interference with the bacterial cell division, abnormal septum 
formation in S. aureus and membrane disruption in E. coli (73). The NPs could prevent 
microbial adhesion to the host cells, biofilm formation, cell invasion and many other modes of 
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pathogenesis. In this regard, NPs are potentially more effective than conventional drugs that 
often have a single target. The similarity between the host defence peptides and the NPs, 
coupled with multiple mechanisms of action against pathogens clearly indicate the potential 
for NPs to act as a novel drug or a drug-lead. Interestingly, other than the direct antimicrobial 
activity to eradicate microbes from the host the NPs show indirect antimicrobial activities. 
Neuropeptides show phagocytosis and anti-inflammatory response which facilitate microbial 
elimination and infection reduction (74). 
 
The above mentioned therapeutic applications were studied against various infections. 
Substance P (SP) was responsible to prevent bacterial colonization in paediatric bronchitis. 
Substance P was also seen responsible in regulating the natural killer cells (INF-γ) production 
and also preventing the growth of P. aeruginosa  (75–77). It was also seen that in the presence 
of E. coli and M. paratuberculosis infection the expression of adrenomedullin was significantly 
higher showing enhanced mucosal immunity (78).  
 
The literature suggests that the neuropeptides have a major role to play in strengthening the 
immune system and creating a line of defence in our system but it might not have an 
overwhelming response as a direct antibacterial agent. However, neuropeptides can be used 
synergistically along with other antibacterials to enhance a response. Considering the 
advantages like low toxicity, small size and amphipathicity of the active sequence, minimal 
side effects, longer shelf life, a natural removal mechanism by the host suggesting low 
rejection, wide range of target organisms and very small chance of bacterial resistance 
generation makes them a strong contender as a future antibacterial agent (79). 
 
 Factors That Determine the Properties of AMP 
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In the search of novel approaches, Antimicrobial peptides have gained popularity amongst the 
researchers as an antibacterial. These so-called ‘natures’ antibiotics’ have shown huge potential 
as antibiotics and overcoming the rising problem of antimicrobial resistance. In 1939 the first 
bacterial antimicrobial peptide was isolated from Bacillus brevis (80,81). This isolate was 
effective in protecting mice against pneumococci infection. This isolate was further purified, 
fractionated and identified as an AMP named as Gramicidin (82). Since then several 
antimicrobial peptides have been successfully developed in pharmaceutical and commercial 
developments. At present, more than 1,000 antimicrobial peptides have been reported from 
numerous different natural and biological sources (83).  
 
To date the relationship between the peptide structure and its function is not very clear. 
Structurally similar peptides have shown varied range of target pathogens and drastically 
different mechanisms of action (34). For example, buforin and magainin 2 are two structurally 
similar peptides; while magainin 2 causes cell lysis by attacking the membrane, the former 
targets the DNA and RNA (84,85). This suggests that the activity of the peptides are not only 
based on their structure but on physiochemical properties like size, charge, hydrophobicity and 
amphipathicity (86). All these factors can lead to changes in the activity of the peptide and are 
responsible for its increased potency or target specificity. These factors are further discussed 
in detail below: 
 
3.7.1. Length 
 
The peptides in general are less than 50 amino acids in length but for antimicrobial peptides, 
the range shortens from 5-25 amino acids. The length of an AMP is very important factor in 
determining its structure and mode of action. A minimum of 7-8 amino acids are required to 
form an amphipathic structure which is ideal for an AMP to transfer onto/into the cell 
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membrane. Based on the known modes of action, the minimum number of amino acids required 
for a barrel-stave formation are at least 22 for α-helical AMPs, whereas 8 amino acids are 
needed for β-sheet AMPs. 
 
The length of the AMP may also be indicative of its cytotoxicity. For example, a shortened 
melittin with 15 residues at its C-terminal (87) and a shorter derivative of HP(2-20) (88) 
exhibited at least 300 times less toxicity to rat erythrocytes and human erythrocytes, 
respectively, compared to their original forms. Thus, it becomes essential to take into 
consideration the length while selecting peptides that may have low toxicity. 
3.7.2. Net Charge 
 
 
The net charge of the peptide is the overall charge calculated as the sum of all the charges of 
amino acids. The overall charge of a peptide could vary from positive to negative. The charge 
has a direct impact on the permeability of the peptide into the membrane. Most of the naturally 
existing antimicrobial peptides are positive in charge. It has been widely reported that the 
charge plays an important role in the peptide and bacterial cell membrane interaction. The 
charge of the bacterial cell membrane is negative, thus, the peptides with a net positive charge 
are most likely to cause cell lysis by disrupting the cell membrane.  
 
Altering the net charge of an AMP can alter its antimicrobial activity. These alterations can be 
done to achieve selective killing of microbes with no or minimized effects on host cells. For 
example, increasing positive net charge of V13K (analog of AMP, L-V13K) from +7 to +10 
resulted in a step-wise increased activity, while decreasing the net charge to lower than +4 
abolished its antibacterial activity against P. aeruginosa  (89). 
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Experiments have confirmed that the overall charge has a directly proportional effect on the 
activity of the peptide. The higher charged exhibited higher potency and spectrum of activity, 
Example: the addition of ten lysine residues to the N-terminus of the antibacterial magainin 2 
drastically increased antibacterial activity without enhancing hemolytic activity. Also, by 
replacing the negatively charged glutamic acid with neutral charged alanine or glutamine 
increased the overall positive charge which led to an increase in the antimicrobial potency (90). 
On the contrary a drop in the positive charge led to the decrease in the antimicrobial activity of 
magainin. (91). 
 
Continuously increasing the positive charge may have a negative effect on the activity of the 
peptide. The following example suggests that there is a threshold limit to increase the positive 
charge beyond which the peptide may start to lose its activity. In the experiment, adding 
positively charged amino acids to a +3 charged peptide P19, improved its potency. Whereas 
the potency at +9 charge was similar to the potency at +11 which suggest that +9 could be the 
optimal positive charge on a peptide to achieve antibacterial activity (92). However, the 
increase in the positive charge cannot solely be conclusive to obtain higher antimicrobial 
activity as the substitutions or the modifications to alter the charge can lead to structural 
modifications in the peptide.  
 
3.7.3. Hydrophobicity 
 
 
The hydrophobicity of a peptide is determined by its intrinsic ability to travel from the aqueous 
phase to the hydrophobic phase. Most of the naturally existing AMPs are composed of almost 
50% hydrophobic residues in their primary amino acid sequence (86). Hydrophobicity along 
with other factors like van der Waals forces, electrostatic interactions and conformational 
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transitions play a major role in the movement of the peptide into the bacterial membrane. It is 
also an important factor in regulating the antibacterial activity and the selectivity of the peptide. 
In order to be membrane-lytic, a peptide must fulfil two requirements. Firstly, it must be soluble 
enough in water so as to transport to the microbial target in sufficient concentration. Secondly, 
it must also be able to interact with the hydrophobic region of the lipid-bilayer to cause 
membrane permeability, hence, it must be hydrophobic. A study with Magainin 2 and 
analogues show that an increase in the hydrophobicity lead to a dramatic increase in the ability 
of the peptide to lyse synthetic anionic vesicles. The study suggested that an increase in the 
hydrophobicity of the peptide will have a similar effect on the bacterial membrane (93). 
However, too high a hydrophobicity would result in self-association, potentially leading to 
precipitation of the peptide in water and would prevent its transportation to the microbial target. 
On the other hand, a peptide with a very low hydrophobicity has an insufficient lipid affinity. 
The increase in the hydrophobicity can change the range of microbial targets. For example, 
Dathe et al. showed that magainin is only effective against gram-negative bacteria in its natural 
form but, on increasing the hydrophobicity of the peptide it can show activity against some 
gram-positive bacteria and eukaryotic cells (94). A similar study showed that the antimicrobial 
activity of cecropin A-melittin was decreased by a single point mutation where an isolucine 
was replaced by serine.(30).  
 
As mentioned above, various studies have been conducted showing that, in most cases, 
increasing the hydrophobicity by increasing the number of aliphatic amino acids generally 
leads to an increase in the antimicrobial activity of the peptide and a decrease in the positive 
charge leads to a reduction in the antimicrobial activity (31). However, a threshold has been 
identified beyond which the activity of the peptide rapidly drops.  
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3.7.4. Amphipathicity 
 
 
Amphipathicity is another factor that correlates with antimicrobial activity of a peptide. It 
perhaps is the most important feature of AMPs as it is crucial for membrane disruption. 
Amphipathicity of a peptide promotes the interaction with the microbial cell membrane(95). It 
can allow the peptides to pass through the outer membrane of bacterial cells to either depolarize 
the cytoplasmic membrane and cause cell lysis, or to pass through the cytoplasmic membrane 
to interact with the inner cellular contents (96). 
 
Amphipathicity rises when a peptide contains distinct hydrophobic and hydrophilic regions as 
a part of its active structure or sequence. Since the cellular membranes are amphiphilic in 
nature, the peptides are likely to have high binding efficiency towards them. Mostly, the AMPs 
have a cationic side to their structure and hydrophobic on the other. On interaction with the 
membrane, the cationic end of the peptide interacts with the lipid head groups, and the 
hydrophobic end penetrates into the lipid-tail region causing disruption to the cell membrane. 
When several peptides accumulate on the cell surface they can carry out pore formations which 
may lead to cell death (97). 
 
A study showed that amphipathicity is more essential than  hydrophobicity for peptide binding 
to the microbial cell membrane as it allows a stronger penetration into the membrane interface 
(98). In an experiment conducted by Zelezetsky et al. it was shown that, increasing the 
hydrophobicity of a peptide resulted in little variation in the MIC values against a range of 
gram-negative and gram-positive bacteria. In contrast, it was observed that in the absence of 
aliphatic, hydrophobic residues, the antibacterial activity of the peptide got completely 
abolished which could be due to the inability of the peptide to enter the bacterial cell membrane 
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(92). Amphipathicity also supports formation of an α-helix which is a highly favourable 
structure for a peptide to have antibacterial property (94,99).  
3.7.5. Hydrophobic Moment 
 
 
The hydrophobic moment is a quantitative measure of peptide amphipathicity. It is defined as 
the vector sum of the hydrophobicities of the individual amino acid (100). Originally, this 
concept was developed to study protein folding, but the more general definitions were 
subsequently found to be applicable to membrane-related protein and peptide structures. The 
hydrophobic moment plot, i.e. the dependence of the hydrophobic moment per residue on the 
mean residue hydrophobicity, may be used to predict the membrane activity of peptide helices. 
According to this plot, membrane lytic peptides tend to cluster in a region of high hydrophobic 
moment and moderate hydrophobicity.  
 
In an attempt to quantify the relationship between hydrophobic moment, hydrophobicity and 
antibacterial activity, it was concluded that hydrophobicity was much less important than the 
hydrophobic moment in predicting the antibacterial activity of a peptide (101). However, 
correlation of the hydrophobic moment and antibacterial activity is not fully reliable because 
of two reasons. Firstly, in many peptides an irregular distribution of hydrophobic and 
hydrophilic regions can lead to an irregular hydrophobic moment. Secondly, the calculation of 
the hydrophobic moment is based on an ideal helix which is difficult to find in the majority of 
AMPs. Nevertheless, Subbalakshmi et al. in her study on a 15-residue long synthetic fragment 
of the bee venom melittin showed that a minor rearrangement of the amino acids in the peptide 
sequence resulted in an increase of the hydrophobic moment which correlated with an increase 
in the antimicrobial activity of the peptide (87). 
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3.7.6. Helicity 
 
 
Even though the helicity of a peptide has no direct correlation with the antibacterial activity of 
the peptide, it can be indicative of the toxicity of the peptide on eukaryotic cells (31). It is also 
thought that the helicity is essential for interaction with neutral lipid membranes present in a 
cell. The non-helical peptides are generally non-active against these neutral lipids. Amino acid 
composition of a peptide has a direct impact on the helicity of the peptide, for example, two 
amino acids, proline and glycine tend to disrupt helix formation. Glycine lacks a side-chain 
and consequently has a high degree of conformational flexibility that does not promote the 
formation of regular secondary structure. Proline is well known as a helix-breaker as it does 
not have an amide hydrogen atom to hydrogen-bond with the other residues. (102). A study 
showed that replacing glycine with leucine or deleting it resulted in enhanced antibacterial 
activity of the peptide melittin (103). Although the literature suggests helicity has no direct 
correlation with the antibacterial activity, its presence does appear to be an advantage. 
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4. Hypothesis and Aims 
 
The emergence of superbugs has led to an urgent need to develop antibacterial agents. The use 
of AMPs and metals appears to be an avenue to deal with resistance. The hypothesis is that the 
use of silver-binding antimicrobial peptides will result in an antibacterial activity that is better 
than each component individually. 
To test the hypothesis, the project has the following aims: 
1. To select potential silver-binding antimicrobial peptides using bioinformatics tools, 
APD, CAMP and CRAN (R-network) 
2. To study the Peptide-Ag(I) binding using NMR and UV-spec 
3. To investigate the antimicrobial potential of apo-peptide and Ag(I)-bound peptides 
based on inhibition and time-kill assays 
4. To determine the cellular location of silver after treatment of bacteria with Ag(I)-bound 
peptides. 
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5. Methodology 
 
 Shortlisting Peptides  
 
With the advent of genome sequencing there are now thousands of peptide sequences known 
to us, out of which, many do not have any known function but some are reported to be 
antibacterial. These reported peptides are available on various databases including the 
Antimicrobial Peptide Database (APD) (104), Collection of Anti-Microbial Peptides 
(CAMPR3) (105), PeptideAtlas Pepbank by Harvard (106) and PubMed. To achieve the first 
objective of this project, some known antimicrobial peptides were identified from these 
databases and then refined based on their ability to bind with silver. The silver binding is 
predicted based on the presence of cysteine and methionine amino acid in the peptide sequence. 
Also, some known neuropeptide sequences were tested for their antibacterial potential using 
the ‘prediction and calculation’ tool available in APD3 and were selected. After the initial 
round of peptide selection, the physiochemical properties of the peptides were estimated before 
experimental testing.  
 
5.1.1. Database Search Tools 
 
5.1.1.1. APD 
The antimicrobial peptide database (APD) (APD, http://aps.unmc.edu/AP/) first came online 
in 2003 and has advanced from APD2 to APD3 over the years. As of January 2018, the 
available version APD3 contains over 2900 AMPs from 6 kingdoms, bacteriocins/bacteria, 
archaea, protists, fungi, plants and animals. This database is manually curated and provides 
searches based on the reported antibacterial, antibiofilm, antifungal, anticancer, antioxidant etc. 
properties of peptides. This vast database allows searches based on peptide name, amino acid 
sequence, peptide motif, length, charge, hydrophobic content, PDB ID, 3D structure, source 
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organism, life domain/kingdom, target microbes, molecular targets and mechanism of action. 
This database is supported with references for its results making it authentic and reliable. The 
unique feature of this database is the ‘prediction and calculation’ tool to predict the 
antimicrobial potential of a peptide. Based on the primary sequence, the tool calculates the net 
charge, hydrophobicity, length, amino acid composition and predicts the structure and the 
possibility of the peptide to be an AMP. Along with the prediction, the database generates five 
peptide sequences similar to the input sequence along with the similarity score. It also works 
in collaboration with other tools and databases including Expasy for Peptide to calculate 
isoelectric point (pI), estimate half-life, calculate instability index and aliphatic index; HLP 
tool for calculating half-life of the peptide in biological environments; ClustalW for peptide 
alignment; CellPPD tool to estimate the peptide’s ability to penetrate the cell (83,104). APD3 
is unique, unified, user-friendly and a comprehensive database for peptide discovery, 
nomenclature, classification, information search, calculations, prediction and design of AMPs. 
 
5.1.1.2. CAMP 
 
Collection of Anti-Microbial Peptides (CAMP) is a comprehensive database of sequences, 
structures and family-specific signatures of prokaryotic and eukaryotic AMPs. 
CAMPR3  (www.camp3.bicnirrh.res.in) is an advanced version of CAMP which has a larger 
database of antimicrobial peptides than many other databases with more than 10,000 entries 
(105). To provide large information, CAMP has combined various tools that aid in sequence 
and structure analysis such as feature calculator, PRATT, ClustalW, Vector Alignment Search 
Tool, BLAST and PDB2PQR. Although there are other databases that provide structural 
information of AMPs, CAMP allows the user to view the structures directly using Jmol viewer. 
Helicity is an important feature of AMPs and helical wheel projection tool is used to predict 
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helicity of the peptide. To make the tool user friendly, most of the inputs and information 
related to the peptides is linked with uniProt and Pubmed (107). CAMPR3 with its large data 
and multifunctional properties is a very important tool in order to design or discover new 
AMPs. 
5.1.2. Database Search 
 
Using the two databases APD3 and CAMPR3, peptides were identified and based on their ability 
to bind silver. A total of 44 peptides were longlisted (Table 9- Appendix 1). Silver is known to 
bind with cysteine and methionine amino acids thus, the primary search was based on 
identifying peptides with cysteine and methionine in the primary sequence. Further the peptides 
were eliminated on the basis of number of cysteine residues. As cysteine are known to form 
disulphide bond, which can be important for activity, it was presumed that a large number of 
cysteine amino acids would interfere with silver binding. Thus, the peptides with more than 
two cysteines were eliminated. Further, the remaining peptides were eliminated on the basis of 
charge and hydrophobicity, the peptides containing a charge of more than +5 and 
hydrophobicity other than 50 ± 10% were eliminated. From the remaining peptides, three 
peptides were selected based on the location of the cysteine and methionine in the sequence. 
The methionine spacing is based on the spacing observed in the known silver-binding peptide 
neurokinin B, i.e. at least six to ten amino acids apart (M(X)6-10M).  
 
Second selection of peptides was made based on the predicted antimicrobial activity of 
different neuropeptides. Previous studies of neuropeptides have highlighted their potential to 
bind metals and these were also included in the peptide list (Table 10-appendix 1). Human 
tachykinin neuropeptides, Substance P (SP), Neurokinin A (NKA) and Neurokinin B (NKB) 
are known to bind copper and silver, and they have the amphipathic nature required for 
antimicrobial activity. Furthermore, modifications to the known peptides by introducing silver 
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binding sites were tested. Specifically, a methionine (‘M’RPKPQQFFGLM) was introduced at 
position 1 in Substance P (RPKPQQFFGLM). This mimics the known silver-binding site in 
NKB (108). The tool ‘prediction and calculation’ available in APD3 was used to predict the 
structure and antimicrobial potential of the peptides. Based on the predictions, mutated (M1) 
substance P (M1SP) and NKB were shortlisted for practical testing.  
5.1.3. Computation of Physiochemical Properties of Peptides 
As mentioned earlier, the function of an AMP highly depends on its physiochemical properties 
hence, it was important to have a common platform to compare the physiochemical properties 
of the shortlisted peptides. Based on these properties the antimicrobial potential of each of the 
peptide was predicted and allowed further shortlisting of peptides for experimental analysis. 
All the shortlisted peptides were assessed using “The R project”. R is free software that 
performs statistical computing and data analysis. R has various pre-stored packages that are a 
collection of different functions and datasets for easy and quick computation. One of the 
package is the ‘Peptides’ package that contains thirteen functions to calculate physiochemical 
properties of a peptides. Unlike other prediction software, R mathematically calculates the 
properties without any restriction on the length of the peptide. It only requires the amino acid 
sequence for the calculation. Some of the functions tested using R were: 
 
1. Molecular weight 
This function calculates the molecular weight of the peptide as the sum of the mass of each 
amino acid in Daltons (Da). It uses the same formula weights given in the Expasy tool. The 
following function is used to calculate the molecular weight: 
      > mw (seq = "amino acid single letter code") 
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Potential antimicrobial peptides are expected to have a molecular weight less than 10,000 KDa. 
Smaller molecular weight helps the peptide to easily traverse through the cell membrane into 
the cell. 
 
2. Net charge 
A higher positive net charge is associated with higher antimicrobial activity of the peptide since 
it facilitates membrane transfer because of favourable interactions with the negatively charged 
phosphates. Most of the antimicrobial peptides are positively charged (+2 to +9). The R 
network calculates the net charge based on a variation of the Henderson Hasselbalch equation 
given by Moore (109): 
 
 
 
 
Where, N are the number of amino acids, ’i’ represent acidic amino acids, aspartic acid, 
glutamic acid, cysteine and tyrosine and ‘j’ represents the basic amino acids. R allows the 
selection of pH and the pKa scale. In the project, all the peptides were tested at pH 7 using the 
EMBOSS scale. The following function is used to calculate the net charge: 
> charge (seq = "amino acid single letter code", pH = 7, pKscale = "EMBOSS") 
 
3. Aliphatic index 
The aliphatic index of a peptide is related to the hydrophobicity and is considered to be mainly 
dependent on four amino acids, alanine, valine, isoleucine and leucine. A higher aliphatic index 
value is said to be related to higher antimicrobial activity and thermostability of a peptide (110). 
R computes the aliphatic index based on the following equation given by Ikai (111). 
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AI = XA + 2.9XV + 3.9 (XI + XL) 
 
Where, XA, XV, XI and XL are the mole percent (100 x mole fraction) of alanine, valine, 
isoleucine and leucine respectively. The following is the function used to calculate the aliphatic 
index: 
> aindex (seq = "amino acid single letter code")  
 
4. Instability index 
R calculates the stability of a peptide using the equation given by Guruprasad et al (112). The 
instability index (II) computes the stability of a peptide in vivo based on its amino acid 
composition. The index value predicts the likelihood of a peptide to get degraded in vivo. It is 
thought that most peptides with an instability index value less than 40 have an in vivo half-life 
more than five hour. Whereas, the instability index value of more than 40 is said to be unstable 
with the in vivo half-life of less than five hours (113). The II is calculated using the following 
formula: 
 
 
 
Where, L is the length of the amino acid sequence, XiYi is a dipeptide and DIWV is the 
dipeptide weight value of stable proteins in the sequence. The following function is used to 
calculate the instability index: 
 
> instaindex(seq = "amino acid single letter code") 
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5. Boman index 
The Boman Index (BI) is a thermodynamic estimate of the potential of peptides to bind to other 
proteins, such as different receptors, and is defined as the sum of the free energies of the amino 
acid residue side chains divided by the total number of amino acid residues. The BI was 
proposed by Boman in 2003 (53). BI value is calculated as the sum of the solubilities of each 
amino acid in the sequence divided by the length of sequence. BI values can be used to 
differentiate between hormones and antimicrobial peptides. It can be calculated by the 
following equation:  
 
 
 
 
An index value of more than 2.48 is expected to have higher binding potential and is most 
likely to be multifunctional like hormones. Small index values (≤1) suggest that the peptide 
would have antibacterial potential with minimum side effects and the negative value indicate 
high antibacterial potential (53). The following is the function used to calculate the Boman 
index: 
> boman (seq = "amino acid single letter code") 
 
6. Hydrophobic Moment Index 
The quantitative measure of the amphiphilicity perpendicular to the axis of any periodic peptide 
structure is called the hydrophobic moment (H moment) (i.e.  the vector sum of 
hydrophobicities). The hydrophobic moment is smaller when the hydrophilic and hydrophobic 
residues are evenly distributed on either side of the peptide backbone. Hydrophobic moment 
less than 0.2 suggest high transmembrane activity (114). Since membrane penetration is the 
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main mechanism of action of most AMPs, values under 0.2 are expected to show antimicrobial 
activity. H moment is calculated based on the type of side chains. The R network predicts the 
H moment based on two orientations of the side chain about the helix axis; first, a-helix 
orientation at 100o angle and second, β-strands orientated at 160o angle. Since the side chain 
conformation of all the peptides are unknown, the H moment is calculated for both side chains 
with a default window (A sequence fraction length) length of 11 amino acid residues based on 
the following equation: 
 
 
 
Where, N is the length of the amino acid, Hn is the hydrophobicity of the nth amino acid and 
δn is the angle based on the peptides orientation. The following is the function used to calculate 
the H moment index: 
> hmoment (seq = "amino acid single letter code", angle = 100, window = 11)  
> hmoment (seq = "amino acid single letter code", angle = 160, window = 11)  
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 Peptide-Metal Binding 
 
5.2.1. Peptides 
All peptides other than Substance P were synthesized by Synpeptide (Shanghai, China). 
Substance P was purchased from Sigma Aldrich (Castle Hill, Australia). Peptide sequences are 
given in Table 1. All the synthesized peptides were more than 95% percent pure and were used 
without further purification. 
Table 1. Peptide and their sequence 
Peptide Name Sequence 
Neurokinin B Asp-Met-His-Asp-Phe-Phe-Val-Gly-Leu-Met-NH2 
Substance P Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met- NH2 
Latarcin 3b Ser-Trp-Ala-Ser-Met-Ala-Lys-Lys-Leu-Lys-Glu-Tyr-Met-Glu-
Lys-Leu-Lys-Gln-Arg-Ala 
Tigerinin 1 Phe-Cys-Thr-Met-Ile-Pro-Ile-Pro-Arg-Cys-Tyr 
Pleurain R1 Cys-Val-His-Trp-Met-Thr-Asn-Thr-Ala-Arg-Thr-Ala-Cys-Ile-
Ala-Pro 
M1Substance P Met-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met 
 
The concentrations of the peptides were calculated manually using NanoDrop 2000c UV-vis 
spectrophotometer (Thermo Scientific) based on the extinction coefficient values derived from 
their amino acid sequences. The concentration of NKB, Substance P and M1SP was calculated 
using the extinction coefficient of the two phenylalanine residues at 259 nm (190 M–1cm–1 × 
number of phenylalanines). The concentration of latarcin 3b, tigerinin 1 and pleurain R1 was 
calculated based on the extinction coefficient of tryptophan and tyrosine residues at 280 nm 
(5690 M–1cm–1 × number of tryptophan, 1280 M–1cm–1 × number of tyrosines). 
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5.2.2. Peptide-Ag(I) Complex Formation 
 
Silver was prepared by dissolving AgNO3 (Sigma Aldrich) in millipore water and the 
concentration was determined based on weight of AgNO3. All silver solutions were used only 
on the day of preparation. The peptide-Ag(I) complexes were prepared by adding freshly 
prepared aqueous silver(I) to the peptide and incubating it for 5 minutes at room temperature.  
 
5.2.3. Nuclear Magnetic Resonance (NMR) 
 
NMR is a technique used for the determination of structures of proteins and peptides in both 
solid and solution state. NMR can record changes in the chemical shift of amino acid protons 
as a consequence of structural changes induced by coordination between metal and peptide 
(115). Silver(I) is a diamagnetic metal ion and therefore can be used in NMR experiments. To 
analyse the peptide-silver interaction one dimensional 1H NMR spectra was obtained using a 
Bruker Avance 300 MHz NMR spectrometer equipped with a 5mm TXI BBI probe controlled 
by TopSpin 1.3 software (Bruker Biospin, Germany). Routinely, 64K complex points were 
acquired over a spectral width of 11 ppm and the data was processed using a π/2 shifted sine-
squared window function with no added line-broadening. The peptides, latarcin 3b, pleurain 
R1, tigerinin 1 and M1SP were tested for their interaction with Ag(I). Previous studies have 
established the ability of NKB and SP to bind Ag(I) (108,116). Each of the peptides were tested 
at a concentration of ∼0.3 mM dissolved in either water or phosphate buffered saline (PBS) 
with the addition of 10% D2O to make up a volume of 400 µl. After the acquisition of the apo-
peptide spectrum an equimolar amount of Ag(I) was added  
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5.2.4. UV-Vis Analysis 
 
UV-Vis analysis was conducted using a Cary 100 UV-Vis spectrophotometer (Agilent). The 
apo-peptide and Ag(I)-loaded peptides were scanned between 200-800 nm and data was 
recorded at an interval of 1 nm using WinUV software version 4.20(468). The spectra were 
processed using Microsoft Excel and plotted using Origin.  
 
To study the role of cysteine residues in pleurain R1, pleurain R1 was treated with reductants 
to reduce any disulphide bonds prior to addition of Ag(I) and then analysed by UV/Vis 
spectroscopy. Pleurain R1 was prepared in PBS (pH 8) at 200 μM concentration, then to reduce 
the disulphide bonds, 500 μM Dithiothreitol (DTT) was added to the sample. After the addition 
of DTT the sample was kept in the water bath at 37oC for 1 hour to carry out the reduction 
reaction. A sephadex G10 size exclusion column was prepared and equilibrated with PBS (pH 
6) before use. The pleurain R1/DTT sample was added to the column and washed through using 
500 μL aliquots of PBS pH 6. A total of nine 500 μL fractions were collected from the column. 
Each fraction was then scanned using Cary 100 UV-Vis spectrophotometer (Agilent). The 
sample containing highest concentration of pleurain R1 was then analysed for binding with 
equimolar silver. The spectra were processed using Microsoft Excel and plotted using Origin.  
 
 Antimicrobial Activity Determination 
 
5.3.1. Bacterial Preparation 
 
The bacterial strains used were ATCC8739 for E. coli and ATCC27853 for P. aeruginosa and 
were obtained from American Type Culture Collection. The strains were grown in Nutrient 
Broth (NB) broth and maintained on Nutrient agar (NA) plates for all the experiments. E. coli 
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and P. aeruginosa cells used, were in exponential phase. The cells were grown overnight at 
37°C to early log phase, OD 595 of 0.3 at 180 rpm in an incubator shaker (Thermoline). 
 
The overnight grown E. coli and P. aeruginosa strains were sub cultured into fresh medium at 
1:50 ratio, i.e. 100 μl in 5mL of nutrient broth. P. aeruginosa and E. coli cultures after 4 hrs 
and 2 hrs respectively were tested for its optical density at 595 nm to lie between 0.08 – 0.13. 
As per the referred protocol, the optical density between 0.08 – 0.13 is equivalent to 
1x108 ~1.5x108 cfu (colony forming unit) which is ideal for antibacterial testing. These 
inoculums were further used for the quantitatively determining the minimum inhibitory 
concentration (MIC) using Percentage inhibition and time-kill assay. The MIC by definition is 
the lowest concentration of antimicrobial agent that completely inhibits the bacterial growth 
(117). 
 
5.3.2. Percentage Inhibition 
 
Percentage inhibition in terms of antibacterial potential is defined as the effect of an 
antibacterial on the rate of bacterial growth. An antibacterial with high activity would result in 
complete inhibition of the bacterial growth by the end of 16 hours. To test the antibacterial 
potential of the peptides and their metal complexes against  E. coli and P. aeruginosa, the 
percentage inhibition experiment was performed using a nitroblue tetrazolium  (NBT) micro 
broth dilution assay (117). The mean percentage inhibition was calculated as: % 𝐼𝐼𝐼𝐼ℎ𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝐼𝐼 =  (1 − (𝐴𝐴𝑖𝑖16 − 𝐴𝐴𝑖𝑖0)/𝐴𝐴𝑐𝑐𝑖𝑖𝐼𝐼𝑖𝑖𝑐𝑐𝑖𝑖𝑐𝑐16 − 𝐴𝐴𝑐𝑐𝑖𝑖𝐼𝐼𝑖𝑖𝑐𝑐𝑖𝑖𝑐𝑐0)𝑋𝑋100 
where At16 and At0 are absorbance readings of test compounds and Acontrol16 and Acontrol0 are 
absorbance readings of growth control at 16 and 0 h, respectively. The MIC was taken as a 
minimal value of extract showing more than 90% inhibition (118) 
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The peptide and peptide-Ag(I) test samples were prepared in the nutrient broth at different test 
concentrations and were tested against E. coli and P. aeruginosa in separate 96 well flat-bottom 
plates. To each of the wells 100 μl of test samples were added in triplicates and control wells 
contained 200 μl of inoculum (5×105 cfu/mL) only or 200 μl of nutrient broth only as a blank. 
The lid was placed on the plate and it was incubated overnight at 37oC in an incubator. Optical 
density readings were taken using a Flurostar OPTIMA plate reader at 595 nm at 0 hrs after 
inoculation. After overnight incubation, the growth or the inhibition of the cells test sample 
could be visually seen. To determine the cell growth, the NBT reduction assay was used. NBT 
was prepared at 5 mg/mL in water and to each of the wells in the 96-well plate 25 μl of NBT 
solution was added then the plate was incubated for 6 hrs at 37oC. After incubation the blue 
colour in the wells was observed. The intensity of the blue colour is proportional to the number 
of living cells. The samples were decanted from the wells by inverting the plate and 100 μl 
DMSO was added to each well. DMSO stops the formazan production and dissolves the blue 
crystals. The absorbance at 595 nm of each of the wells was determined using a Fluorostar 
OPTIMA plate. The observations were recorded for each of the samples. Further the percentage 
inhibition was mathematically calculated (119). This method was the first way in which 
peptides were tested and allowed some peptides to be eliminated from further testing. 
 
5.3.3. Time-Kill Curve Analysis 
 
The time kill analysis is a clear representation of the effect of the antibacterial concentration 
on the bacteria with respect to time. It is more accurate and a valid test to determine the MIC 
of the antibacterial (120). The peptide and peptide-Ag(I) test samples were prepared in the 
nutrient broth at different test concentrations and were tested against E. coli and P. aeruginosa 
in separate 96 well flat-bottom plates for a period of 16 hrs as described above. The absorbance 
at 570 nm of the wells were taken at every 5 minutes using the Flurostar OPTIMA plate reader. 
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To obtain the time-kill growth curve absorbance values were plotted against different time 
intervals (121).  
 
Based on the above analysis the peptide-Ag(I) complex is said to be synergistic, additive or 
antagonistic effect against the bacteria. A complex is said to show synergy when its combined 
MIC is significantly lower than the sum of their individual MICs. It is said to be antagonistic 
when the combined MIC is higher than the sum of individual MICs and it is additive when the 
combined effect is equal to the sum of the individual MICs. Quantitatively the synergy is 
determined in terms of fractional inhibitory concentration (FIC). The FIC is calculated based 
on the following equations: 
FICA= MICA+B/ MICA 
FICB= MICB+A/ MICB 
FICINDEX = FICA+FICB 
 
Where, MICA is the MIC value of antibacterial A by itself, MICB is the MIC value of 
antibacterial B by itself and MICA+B is the MIC of antibacterial A in combination with 
antibacterial B. The FIC value ≤0.5 suggests synergy and the values between 0.5-1 suggest an 
additive effect (119). 
 
 Subcellular Fractionation of P. aeruginosa 
 
The AMPs are known to attack the bacterial cells either extracellularly on the cell membrane 
or intracellularly by binding to various proteins and nucleic acids essential for the cells survival. 
The metallo-peptides showing highest antibacterial activity were studied for their effective site 
of target within the bacteria. The bacterial cells were fractionated in cytoplasmic, periplasmic 
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and crude membrane fractions. Each fraction was then studied for the presence of Ag(I). The 
cell fraction having the highest concentration of silver was assumed to be the site of action for 
the metallopeptide. The concentration of silver in each fraction was determined using Atomic 
Absorption Spectroscopy and the protein content was determined using the BCA protein assay 
kit as per manufacturer’s instructions (ThermoFisher Scientific). The amount of Ag(I) in each 
fraction was normalized by dividing the Ag(I) concentration by the protein concentration in 
each fraction.  
 
5.4.1. Sub-Fractionation 
The bacterial cells (1 L) grown overnight were pelleted using the Heraeous Multifuge X3R 
centrifuge by Thermo scientific. The pellet obtained was suspended in 10 mL 0.2 M Tris buffer 
pH 8, 1 M sucrose, 1 mM EDTA and lysozyme was added to a final concentration of 1 mg/mL. 
The suspension was mixed and incubated for 5 min at RT. 40 mL milli-Q H2O was added to 
the swirling mixture before placing on ice. The cells were then centrifuged at 200 000× g for 
45 min at 4 °C (Sorvall wX+ Ultra series centrifuge). The supernatant contained the periplasmic 
fraction. The pellet was resuspended in 7.5 mL ice-cold 10 mM Tris-HCl pH 7.5, 5 mM EDTA, 
0.2 mM DTT supplemented with 50 µL DNAse (1 mg/mL). The cells were ruptured using an 
ultrasonicator (Branson digital sonifier) for 5 min and 30 % amplitude with a pulse of 0.05 sec 
on and off time for 5 minutes. The cell debris was spun down by centrifugation at 4000 rpm 
for 10 min at 4 °C. Then the supernatant was centrifuged at 280 000-300 000× g for 2-4 h at 4 
°C. The supernatant contained the cytoplasmic fraction and the pellet contained the crude 
membranes. 
 
5.4.2. Atomic Absorption Spectroscopy (AAS): 
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AAS is used to detect and determine the presence and concentration of metallic elements in a 
sample (liquid). AAS is based on the principle that metals in a gaseous state will absorb specific 
frequencies of light (122). The silver concentration in each sub-cellular fraction was 
determined using a 200 Series Atomic Absorption System equipped with a 328.1 nm lamp 
(Agilent). Each cell fraction was acidified using 32.5% nitric acid to a final acid concentration 
of 16.25% (AA grade). Standards were prepared for silver at 100 µM, 70 µM, 40 µM and 10 
µM in 32.5% nitric acid.  
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6. Results and Discussion 
 
 Peptide Selection 
 
Using the bioinformatics tools, APD and CAMP, four peptides were shortlisted based on their 
potential to bind silver, their charge and their hydrophobicity. Three of the peptides are natural 
products occurring in different species from the Asia region. Namely, latarcin 3b has been 
isolated from Lachesana tarabaevi (ant spider) venom, tigerinin 1 has been isolated from skin 
secretions of an Indian frog, Rana tigerina, and pleurain R1 has been isolated from skin 
secretions of a Chinese frog, Rana pleuraden. The fourth peptide is substance P which is a 
known neuropeptide in humans (Table 2). 
 
Table 2  Shortlisted antimicrobial peptides based on Predicted silver metal binding 
 
 
Using the ‘peptide prediction’ tool available at APD3 antimicrobial potential for unknown 
antimicrobial peptides were determined. Based on the results, two peptides, neurokinin B 
(NKB) and M1 Substance P (M1SP) were selected for further experiments (Table 3). Both the 
peptides are predicted to form an α-helix and have a high protein binding potential (boman 
index), both suggesting high antibacterial activity. 
Name Sequence Source 
Organism 
Total net 
Charge 
Hydrophobicity 
Latarcin 3b  SWASMAKKLKEYMEK
LKQRA 
Snake +5 40% 
Tigerinin-1 FCTMIPIPRCY-NH2 Frog (India) +1 54% 
Pleurain-R1 CVHWMTNTARTACIAP Frog (China) +1 
 
56% 
Substance P RPKPQQFFGLM-NH2 Homo sapiens +3 36% 
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Table 3 Shortlisted peptides based on prediction tools 
 
Name Sequence Protein binding 
potential (kcal/mol) 
Structure 
prediction  
Neurokinin B DMHDFFVGLMG-NH2 0.05 α- helices 
M1 Substance P MRPKPQQFFGLM-NH2 1.25 α- helices 
 
 
 Prediction of Antimicrobial Potential Using Comprehensive R 
Archive Network   
 
The shortlisted antimicrobial peptides were further studied for their theoretical potential as 
antimicrobial agents based on their physiochemical properties. The peptides were studied for 
other antimicrobial properties like molecular weight, charge, instability index, hydrophobic 
moment and boman index using the Comprehensive R Archive Network (Table 4). 
 
Table 4 Physiochemical properties of peptides using Comprehensive R Archive Network 
 
 
 Molecular 
Weight 
Net 
Charge 
Aliphatic 
Index 
Instability 
Index 
Boman 
Index 
H 
moment 
100o 
H moment 
160 o 
Latarcin 3b 2426.9 +3.97 54 24.9 2.32 0.45 0.36 
Pleurain R1 1775.09 +1.15  61.25 
 
40.6 0.76 
 
0.28 0.21 
Tigerinin 1 1343.68 +0.91  70.90 
 
26.63 -0.009 0.31 0.24 
Substance P 1348.62 +1.97 35.4 47.9 
 
1.58 0.23 0.35 
M1 
Substance P 
1479.82 +1.97 38.4 38.4 1.25 0.26 0.37 
Neurokinin B 1268.46 -1.78 61.8 46.5 0.05 
 
0.27 
 
0.20 
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All the shortlisted peptides have a molecular weight less than 10,000 KDa which suggests that 
the peptides have an ideal molecular weight to be able to penetrate the cell membrane and show 
an intracellular or extracellular mechanism.  
 
Latarcin 3b due to its very high charge (total net charge and net charge at pH 7) and stability is 
likely to show the highest activity. Its boman index close to 2.38, which is the threshold for 
multifunctional and hormone-like peptides. Thus, it would be fair to expect a high antibacterial 
from the peptide alone and in combination with silver.   
 
Tigerinin 1 being the smallest sequence may show some interesting results as its small size 
either would enable it to penetrate the membrane easily but it may limit it from forming a 
transmembrane structure. Despite its small size, its high stability and richness in silver binding 
amino acids may result in a highly stable peptide-metal complex which may show increased 
antibacterial activity.  
 
NKB, being a neuropeptide that is known for its short half-life, a similar result was observed 
as per the instability index that suggested low in vivo stability.  Despite the smallest charge, 
NKB shows high aliphatic index value and a low H moment making it one of the more 
favourable peptides to experimentally test in antimicrobial assays. 
 
Pleurain R1 is a marginally stable peptide with 0.2 H moment value in both the predicted 
orientations. Antimicrobial peptides are principally known to act on the cellular membrane. 
Typically, the peptides showing a transmembrane activity have large hydrophobicity and low 
H moment value (123). Based on this rule, pleurain R1 has a great potential as a transmembrane 
protein.  
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Substance P and M1 Substance P showed similar physiochemical properties. However, the 
additional methionine has affected the aliphatic index, boman index and instability index values 
making the peptide more aliphatic, stable and more interactive with other proteins. The 
mutation has the largest effect on the stability making M1SP a stable amino acid with the 
instability index value decreasing from 47.9 to 38.4. Thus, both the peptides are selected to 
study the effect of antimicrobial peptides and to also see the combinatorial effect of each of the 
peptides with silver.  
 
The presence of arginine is another factor to predict high antimicrobial activity. Arginine is a 
basic amino acid (pKa ~ 10) and retains a positive charge at biological pH and therefore 
supports initial membrane interactions. Peptides containing this amino acid are  expected to 
show high antimicrobial activity (97) The peptides latarcin 3b, pleurain R1, tigerinin 1, 
substance P and M1SP are likely to show higher activity due to the presence of arginine.  
 
Some of the amino acids may have a negative effect on the antimicrobial activity of a peptide. 
For example, as noted previously, the presence of proline and glycine prevents helix formation, 
which is a highly preferred structure for antibacterial activity. Thus, the presence of these two 
amino acids may have a limiting effect on tigerinin 1, pleurain R1, substance P, M1SP and 
NKB. Note that all of the peptide properties discussed above were unable to be determined in 
the presence of silver. Therefore, although useful to help sort peptides the effect of silver on 
these properties is not known. 
 
 Shortlisted Antimicrobial Peptides 
 
Based on the silver binding ability and the predicted antimicrobial potential, the following 
peptides were studied experimentally for their activity. 
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6.3.1. Latarcin 3b 
 
Over the years survival techniques have evolved across all the species, the venomous animals 
have been using their venom for attacking their prey and for self-defence. The venom 
composition is often complex, it comprises ions, biogenic amines, polyamines, polypeptide 
neurotoxins, cytolytic peptides and enzymes. (124). The venom can also containa large pool of 
various antimicrobial peptides. Latarcins are a group of cytolytic peptides obtained from the 
venom of the spider Lachesana tarabaevi.  About seven groups of latarcins are known to us 
from Latarcin1-7. Latarcins are strongly cationic molecules with isoelectric point (pI) >10, and 
the net charge at pH 7 varies from +5 for Latarcin 3b to +10 for latarcin 5. 
 
Our peptide of interest is latarcin 3b (SWASMAKKLKEYMEKLKQRA), which forms a helix 
in water (>30% α-helix), which is unusual for short linear peptides. The reported MIC of 
latarcin 3b against E. coli is between 23-28 μM and against P. aeruginosa is >40 μM (124). 
 
6.3.2. Tigerinin 1 
 
Amphibians are one of the larger sources of antimicrobial peptides. Amphibians live on both 
land and water and are exposed to variety of different conditions full of pathogenic 
microorganism. Their survival ability is aided by the presence of a large number of 
antimicrobial peptides as a part of their chemical defence system (125). The discovery of 
magainins from Xenopus laevis brought attention to amphibians as a source of AMPs. Rana 
tigerina, an Indian frog, is the source of a novel family of short, non-helical antimicrobial 
peptides called tigerinins. Tigerinins are a unique family of 11 to 12 residue peptides and are 
characterized by the presence of a stretch of predominantly hydrophobic amino acids with one 
cationic residue and an amidated C terminus (126). They also contain two cysteine residues 
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linked by a disulphide bond to form a loop of nine amino acid residues making them distinctly 
different from any other known AMPs. The peptide Tigerinin 1 is one of the most active 
member from this peptide family (127).   
 
Structurally, tigerinin1 has an unordered β-turn conformation. The MIC of the peptide tigerinin 
1 was determined against Pseudomonas putida, Micrococcus luteus, Bacillus subtilis, 
Staphylococcus aureus and Escherichia coli. Tigerinin1 was able to inhibit the growth against 
E. coli and P. putida at 40 µg/mL, Bacillus subtilis and Staphylococcus aureus at 30 µg /mL 
and, Micrococcus luteus at 20 µg /mL. Tigerinin 1 showed 60-80% killing of the 
microorganisms in the first 5 minutes of incubation. This rapid killing is reported to suggest 
membrane permeability. A study conducted by Purna et al. showed that the peptide tigerinin 1 
showed highly effective membrane permeabilization against E. coli. Further investigation into 
the structure-function activity it was concluded that β-turn structure stabilized by the disulphide 
bridge is essential for the activity of tigerinin 1 (126).  
 
6.3.3. Pleurain R1 
 
Another shortlisted amphibian is pleurain R1, isolated from the skin secretions of R. pleuraden 
frog found in subtropical plateau region of Southwest of China. Pleurain R1 is a part of the 
amino-terminal copper and nickel (ATCUN) binding unit group of AMPs (128). The ATCUN 
unit, H2N-AA1-AA2-His3 is a naturally occurring feature in several peptides and proteins that 
are known to bind copper and nickel (129). ATCU sites are known to increase membrane 
permeability and enhance the antimicrobial activity. The reported MICs of pleurain R1 against 
E. coli is 100 µg/mL, S. aureus is 25µg/mL and Candida albicans is 50µg/mL (130). 
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6.3.4. Neurokinin B 
 
 
Neurokinin B is a neuropeptide which belongs to the family of tachykinin peptides. Encoded 
byTAC3 gene, NKB largely controls reproductive function in conjunction kisspeptin an 
dynophin in humans. Like other members of the tachykinin family NKB has neuro-
inflammatory, neuro-immunological, and neuroprotective functions (131). NKB contains 
hydrophilic and hydrophobic domains and an ATCUN motif that helps metal binding and two 
methionine amino acids. It will bind Ag(I), Cu(I), Cu(I) and Ni(II)(132–134).  
 
6.3.5. Substance P 
 
Substance P is a known antimicrobial peptide and is a member of the tachykinin family of 
neuropeptides (135). Having said that, like many other neuropeptides it shows multiple 
functionalities like pain signal transmission, homeostatic functions and mediating immune 
responses and inflammation. Substance P is an undecapeptide, composed of eleven amino acid 
(RPKPQQFFGLM-NH2) and has a net charge of +3 and 36% hydrophobicity at pH 7.4. 
Various studies have shown that Substance P has a strong antimicrobial activity against both 
gram negative and gram positive bacteria (136,137). The MIC against E. coli was 5.7 µg/mL 
and against P. aeruginosa was 15 µg/mL. The experiment conducted by Kowalasky et al. 
shows that Substance P has a direct effect on the bacteria and is not receptor mediated. SP also 
showed antifungal activity against C. albicans at MIC 8 µg/mL (135). 
 
6.3.6. M1 Substance P 
 
 
Substance P is thought to bind silver via the single methionine (116). However, silver usually 
forms linear two-coordinate complexes as observed in NKB, and the binding to Substance P is 
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likely to involve dimer formation. To generate a peptide that will bind with a 1:1 stoichiometry 
a mutant peptide was generated.    A methionine was added at the first position of Substance P 
to obtain a similar sequence to Neurokinin B.  
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 Analysis of Peptide Silver Binding by NMR and UV/Vis 
Spectroscopy. 
 
Silver is known to bind to methionine and cysteine amino acids by coordinating to the side-
chain sulphur atoms (133). Substance P and NKB have already been reported to bind to Ag(I) 
(116,138,139). The peptides latarcin 3b, pleurain R1, tigerinin 1 and M1SP were tested for their 
ability to bind Ag(I) using NMR and electronic (UV/Vis) spectroscopy. The following are the 
NMR results for the different peptides and Ag(I) binding. 
 
6.4.1. Latarcin 3b 
 
 
Latarcin 3b (SWASMAKKLKEYMEKLKQRA) contains two methionine (M5 and M13) which 
suggest it should be able to bind Ag(I). NMR spectra were collected for apo-latarcin 3b at 0.3 
mM concentration and after the addition of equimolar Ag(I) (0.3 mM) at pH 5 (Figure 3).  On 
addition of silver the peaks were seen to shift.  The major shift was observed for peaks 
associated with methionine protons and for protons in the in the amide region. The aliphatic 
region of the NMR spectrum of apo-latarcin 3b (Figure 3A) showed two distinct peaks at 2.06 
ppm and 2.10 ppm which can be assigned to the two Met ε-CH3 groups and a set of peaks at 
2.60 ppm assigned to the γ-CH2 of methionine. On addition of silver the two α-CH3 have shifted 
to 2.12 ppm and 2.15 ppm and the γ-CH2 group has shifted to 2.66 ppm. There was a slight 
movement in the peaks at 2.1 ppm. The shifts observed are similar to those observed previously 
for the binding of Ag(I) to NKB suggests coordination of Ag+ to the Met sulphur atoms. The 
NMR spectra were obtained at pH 5 and as a result the amide protons are able to be observed 
around 8.1 ppm (Figure 3B). There are distinct changes in the amide region upon the addition 
of Ag+, presumably as a result of conformational changes required to coordinate the metal. The 
identity of the amide protons that have shifted has not been established (although are likely the 
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methionine amide protons), however the shifts further supports the coordination of the Ag(I) 
and the peptide. The NMR data suggests that Ag+ binds to sulphur atoms contributed by the 
methionine atoms as shown in (Figure 3). 
 
Figure 3. NMR spectra of apo-latarcin 3b (0.3mM) (lower trace) and after the addition of 0.3 
mM Ag(I) (upper traces) at ∼ 5 pH showing (A) the aliphatic region showing the peaks at  δ = 
2 ppm assigned to the Met-εCH3 protons (B) chemical shift movement of peaks in the amide 
region (δ ∼ 8.1 ppm) and a lack of movement of peaks in the aromatic region (6.8-7.6 ppm)  
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Figure 4.  Absorbance of latarcin 3b before (black line) and after addition of silver. Inset, shows 
the difference spectrum, with an arrow highlighting the peak at 260 nm due to a S→Ag(I) 
LMCT. 
 
Chemical shift changes to the peaks in the amide region (Figure 3B, 6.8 – 7.6 ppm) shows the 
movement of peaks suggesting conformational changes in the peptide structure. This is most 
likely due to conformational changes as a result of silver coordination to methionine. This 
coordination would result in the formation of a complete ring like structure (Figure 5).  
 
 
Figure 5. Predicted complex between Latarcin 3b and Ag(I) 
 
6.4.2. Pleurain R1 
 
 
Pleurain R1 (CVHWMTNTARTACIAP) contains two cysteine amino acids (C1 and C13) and 
one methionine (M4). Ag(I) is known to bind with both cysteine and methionine but has more 
affinity towards cysteine binding, and it can reasonably be expected that Ag(I) coordinates with 
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cysteine over methionine. NMR spectra were collected for apo-pleurain R1 at 0.3 mM 
concentration and with equal concentration of silver (Ag(I)-pleurain R1, 0.3 mM) in PBS at 
pH 6.8. The scan shows a small peak for the two cysteine in the sequence at 3.7 ppm (βH) and 
a sharp peak for ε-CH3 at 2.1 ppm and peaks for Met γ-CH2 at 2.44 ppm. Upon addition of 
silver no significant shift was observed for Cys and Met4 peaks. However, a minor peak shift 
can be observed in the amide region at 8.10 ppm, which shifts to 8.11 ppm after addition of 
Ag(I).  
 
When expanded (Figure 6) shows very subtle changes in aliphatic protons at chemical shifts 
consistent with Cys1,13 (Hβ, 3.6 ppm) and Met4 side chains upon the addition of silver which 
suggests some interaction with the peptide. However, in contrast to the large chemical shift 
changes observed for latarcin 3b it is likely that pleurain R1 is not binding silver to any extent.  
It is possible that the shift in the amide region is due to the coordination of Ag(I) with the NH2 
groups of the peptide, but it is unlikely that this is a high affinity association (140). 
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Figure 6. NMR spectra of apo-Pleurain R1 (0.3mM) (lower trace) and after the addition of 0.3 
mM Ag(I) (upper traces) at pH 6.8 showing (A) the aliphatic region around d = 2 ppm (B) the 
aromatic and amide region. The arrow highlights the peak shift. 
 
Further to investigate the pleurain-R1 binding with silver, a UV-Vis spectra analysis was 
performed. Apo-pleurain R1 was scanned first followed by the addition of equimolar silver and 
incubation for 8 minutes. The scan showed no evidence for binding between silver and pleurain 
R1 (data not shown). It was assumed that due to the presence of disulphide bonds between 
cysteines, silver was unable to bind. To investigate this pleurain R1 was reduced using the 
reductant DTT. The reduced peptide was purified from residual DTT using a G-10 size-
exclusion column and the reduced pleurain R1 was tested for silver binding. In contrast to the 
previous experiment, the addition of Ag(I) to reduced pleurain R1 generated the spectrum 
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observed in (Figure 7, red line). The difference spectrum (Figure 7, inset) shows the presence 
of a charge-transfer peak at 260 nm indicating sulphur coordination to the metal. 
 
 
Figure 7 Shows the absorbance of Pleurain R1 reduced by DTT coordinated with silver. 
Absorbance of Pleurain R1 before (black line) and after addition of silver. Inset, shows the 
difference spectrum, with an arrow highlighting the peak at 260 nm due to a S→Ag(I) LMCT. 
 
6.4.3. Tigerinin 1  
 
 
Tigerinin 1 (FCTMIPIPRCY) is an 11 amino acid cysteine (C2, C10) and methionine (M4) rich 
peptide. NMR spectra were collected for apo-tigerinin at 0.48 mM concentration and with an 
equal concentration of silver. On addition of silver, cysteine peak showed a slight chemical 
shift change but no change in the methionine peak was observed (Figure 8A). Intriguingly, in 
the amide region (Figure 8B) amide (7.95 ppm) shifts downfield to 8.07 ppm and another shift 
is observed from 8.36 to 8.34 ppm. This is a substantial shift which is difficult to reconcile in 
the absence of a definitive assignment, however it is suggestive of a conformational change. 
However, it is unlikely that a conformational change occurs for just one amide group (no other 
amide proton peaks are affected) so it remains unclear why this amino acid moves. 
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The scan shows a small peak for the two cysteine in the sequence at 3.6 ppm (βH) and a sharp 
peak for α-CH2 at 2.1 ppm and short peak for Meth γ-CH2 at 2.68 ppm. NMR spectra on 
addition of silver the γ-CH2 and α-CH2 peak showed no shift. The βH (Cys) was observed to 
split in two small peaks along with a small rightward shift towards 3.6 ppm (Figure 9). Since 
the shift is so small and with no other evident binding, this shift could be a consequence of the 
ethanol present with the sample.  
 
Figure 8. NMR spectra of apo- Tigerinin 1 (0.48mM) (lower trace) and after the addition of 
0.48 mM Ag(I) (upper traces) at pH 6.8 showing (A) the aliphatic region (B) the aromatic and 
amide region. The arrow highlights the peak shift. 
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Figure 9 Indicates peak formation at 3.6 ppm showing coordination between Ag(I) and 
Cysteine at βH position suggesting no significant shift. Ag(I) + Tigerinin 1 is shown overlaid 
in blue over Apo-Tigerinin1. 
 
6.4.4. M1 Substance P 
 
Mutated Substance P (M1SP, MRPKPQQFFGLM) contains two Methionines (M1, M12) in its 
sequence. NMR spectra were collected for two samples of M1SP (Apo) at 0.3 mM 
concentration and with equal concentration of silver (0.3 mM). The results show a clear 
chemical shift change for the M1, M12 for ε-CH3 peaks and a small change in the amide region. 
 
The scan for Apo-Mutates SP showed two distinct peaks at 2.05 ppm and 2.10 ppm for the two 
methionine ε-CH3 groups followed by a peak at 2.6 for γ-CH2 protons of methionine. On 
addition of silver the two α-CH3 merged together to show a more intense peak and shifted to 
2.15 and the γ-CH2 shifted to 2.64 ppm and became broad. This suggests the coordination of 
Ag+ to the two methionine sulphur atoms. Due to low pH the NH peaks in the amide region 
were observable. The change in the peaks in the amide region 8.10 -8.60 ppm upon addition of 
silver indicate conformational changes (Figure 11). This change further supports the 
coordination of the Ag(I) and the peptide.  
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Figure 10 NMR spectra of apo- M1SP (0.3 mM) (lower trace) and after the addition of 0.30 
mM Ag(I) (upper traces) at pH 6.8 showing (A) the aliphatic region (B) the aromatic and amide 
region 
 
Chemical shift changes to the peaks in the aromatic region (Figure 10B, 6.8 – 7.6 ppm) shows 
the movement of peaks due to phenylalanine sidechain aromatic protons. This is most likely 
due to conformational changes as a result of silver coordination to methionine. This 
coordination would result in the formation of a complete ring like structure (Figure 12).  
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Figure 11 Indicates peak the multiple peak changes in the amide regions at pH 6.8 that shows 
the movement of phenylanilines because of coordination between Ag(I) and methionine. 
Ag(I)+ M1SP is shown overlaid in blue over Apo-M1SP. 
 
 
 
Figure 12 Predicted coordinate formation between Mutated M1SP and Ag(I) 
 
The metal peptide binding was further confirmed by UV-vis analysis. Spectra were collected 
over the range 200 -600 nm before and after the addition of Ag(I) to M1SP (Figure 13). The 
difference spectrum shows a small peak at 220 nm and 260 nm. The peak at 260 nm can be 
attributed to a ligand to metal charge transfer (LMCT) as previously described. This result 
supports the NMR data and further indicates that M1SP can bind Ag(I).  
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Figure 13 Shows the absorbance of M1SP before (black trace) and after addition of Ag(I) (red 
trace). Inset shows the difference spectrum, with an arrow highlighting the peak due to the 
S→Ag(I) LMCT 
 
Discussion: 
 
The NMR an UV-Vis results confirm that silver binds to the two methionine residues in 
Latarcin 3b and M1SP.Thus, both the antimicrobial peptides are expected to show enhanced 
antibacterial activity.  On the other hand, pleurain R1 and tigerinin 1 did not show any 
significant binding. As mentioned earlier, tigerinin 1 is known to form a disulphide bond 
between the two cysteine residues to form a loop of nine amino acids. Thus, due to no available 
silver binding sites, silver does not bind to the peptide. It can also be assumed that the 
methionine binding site was also blocked due to the loop formation. It was assumed that the 
pleurain R1 had a similar structural property. It could also be suggested that the cysteine fail to 
from a coordinate bond with silver due to large number of amino acids present between the two 
(C1, C13). Also, the methionine amino acid could have been blocked by the adjacent 
tryptophan physically blocking silver binding. The assumption of disulphide bond formation 
between the two cysteine residues was confirmed by reducing pleurain R1 and analysing silver 
binding using UV-Vis analysis. After reduction with DTT pleurain showed binding to silver.  
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 Percentage Inhibition 
 
6.5.1. Silver  
 
 
The peptides and their silver complexes were tested for  antimicrobial activity using the nitro 
blue tetrazolium (NBT) assay. Figure 14 shows the effect of Ag(I) alone on P. aeruginosa 
and E. coli at various concentrations.  The graphs show that Ag(I) is active against both the 
bacteria. Figure 14 A suggests the minimum inhibitory concentration against P. aeruginosa 
lies between 0.031- 0.060 mM Ag(I), and the variability in the data makes it difficult to be 
more accurate. Similarly, against E. coli, the MIC lies between 0.031 – 0.125 mM. The 
reported inhibition value lies within the experimental ranges obtained in the literature (141).   
 
 
Figure 14 Inhibition by Ag(I) at different concentrations against A) P. aeruginosa and b) E. 
coli. Error bars represent SEM, n=18. 
 
6.5.2. Neurokinin B (NKB) 
 
 
The antibacterial activity of NKB was tested independently and along with Ag(I) in equal 
concentrations, i.e. as [Ag(I)NKB]. The results clearly indicate improved activity of the peptide 
in the presence of an equal concentration of silver (Figure 15). Unlike the theoretical prediction, 
the antimicrobial activity of NKB was poor against P. aeruginosa. Interestingly, in the presence 
of Ag(I), NKB shows over 100% inhibition at 18.75 µM concentration which is significantly 
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lower than the individual MIC of both NKB and Ag(I). It can be concluded that the [Ag(I)NKB] 
has an enhanced antibacterial effect against P. aeruginosa compared to either component 
alone. However, considering the large error bars and the lack of tested concentrations lower 
than 2.35 µM (Figure 15B) it is difficult to confidently determine the MIC value. However, if 
we consider the lowest concentration of 2.35 µM as the MIC, then the peptide-metal complex 
exhibits synergism. 
 
  
Figure 15 Effect of (A) NKB alone and (B) [Ag(I)NKB] on the viability of P. aeruginosa. Error 
bars represent SEM (A) n=6 and (B) n=6 
 
In contrast to its effect on P. aeruginosa, apo-NKB showed slightly better antibacterial activity 
against E. coli (Figure 16A). Upon coordination of NKB with Ag(I) complete inhibition was 
not observed. But, at the highest concentration of 300 µM close to 90% inhibition was 
observed.  A trend can be observed showing higher inhibition with an increase in the 
concentrations, however, based on 300 µM [AgINKB] as the approximate MIC concentration 
the complex shows a decrease in the independent activity of silver. It appears that in contrast 
to P. aeruginosa, in E. coli coordination of silver to NKB results in the metal losing its 
antibacterial efficiency.  
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Figure 16  Effect of (A) NKB alone and (B) [Ag(I)NKB] on the viability of E. coli. Error bars 
represent SEM (A) n=3 and (B) n=9 
 
6.5.3. Latarcin 3b 
 
 
The antibacterial activity of Latarcin 3b was tested independently and in complex with Ag(I) 
against P. aeruginosa and E. coli. The experimental concentrations chosen were based on the 
reported MIC values of Latarcin 3b against P. aeruginosa (>45 µM) and E. coli(28 µM) 
(124). The results obtained here (Figure 17A, Figure 18A) are inconsistent with the literature, 
as Latarcin 3b had higher activity against P. aeruginosa than E. coli. Latarcin 3b exhibited ~ 
75% inhibition of P. aeruginosa at concentrations > 40 µM (Figure 17A) which is broadly 
consistent with the reported MIC.  After coordination of silver, the MIC was significantly 
improved (Figure 17B). It can be observed that the peptide shows 100% P. aeruginosa  
inhibition at 10 µM concentration. The MIC can be estimated as 5 µM which has ~ 90% 
percentage inhibition. On comparing the individual MICs of the peptide and silver 
independently and the metal-peptide complex, a synergistic response is present. The MIC of 
Ag(I) is improved by at least 3 fold and similar effect is observed for the peptide. 
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Figure 17 Effect of (A) latarcin 3b alone and (B) [Ag(I)Latarcin 3b] on the viability of P. 
aeruginosa. Error bars represent SEM (A) n=15 and (B) n=12 
 
Apo-latarcin 3b was less effective against E. coli in comparison to P. aeruginosa with 
only 15% inhibition at 70 µM concentration. However, the large variability in the inhibition 
percentage suggest negligible activity against E. coli (Figure 18A) which is in complete 
contrast to literature values (28 µM) (124). The coordination of Ag(I) resulted 
in an improvement in the activity of the peptide (Figure 18B). There was less variability in the 
results and the MIC can be estimated at 17.5 µM. The complex shows a mild synergistic 
response - the MIC of Ag(I) was improved at least 2 fold and a similar observation can be made 
for the peptide.   
 
 
Figure 18  Effect of (A) latarcin 3b alone and (B) [Ag(I)Latarcin 3b] on the viability of E. coli. 
Error bars represent SEM (A) n=12 and (B) n=9 
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6.5.4. Pleurain R1 
 
 
Literature values for the MIC value of pleurain R1 against E. coli has been reported as 100 µM, 
and experimental concentrations were selected to encompass this value (130). Since no MIC 
has been reported against P. aeruginosa, the peptide was tested to a concentration of 
250 µM.  The results show that pleurain R1 is moderately effective against P. aeruginosa with 
a trend towards greater inhibition at the higher concentrations (Figure 19).  However, the 
variability in the data makes it difficult to suggest there is any significant effect against 
P. aeruginosa.  The inhibition is considerably improved by the coordination of silver. Because 
of large error bar at 15 µM the MIC value was estimated as 20 µM but is likely slight lower 
than this (15 µM < MIC < 20 µM) (Figure 19B) . The MIC of silver alone is around 30 µM it 
is likely that the inhibition observed with pleurian R1 is mostly due to silver alone. Indeed, the 
NMR and UV/Vis data suggested very little coordination of silver to pleurain R1 which 
supports the idea that silver is acting alone in these inhibition experiments. 
 
 
Figure 19 Effect of (A) pleurain R1 alone and (B) [Ag(I)pleurain R1] on the viability of P. 
aeruginosa. Error bars represent SEM (A) n=9 and (B) n=9 
 
Against E. coli, pleurain R1 exhibited an increasing inhibiting trend with the increase in the 
peptide concentration. In spite of this the peptide showed no more than 30% of inhibition at 
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the highest test concentration. Also, in contrast to the reported MIC, in these experiments the 
peptide shows only about 10% inhibition at the reported MIC concentration (Figure 20B).   
Even though the activity of the peptide appears to improve in the presence of silver, the large 
error bars make the results unreliable. Considering the variability, all the concentrations seem 
to show similar antibacterial response. The silver-complex did not show complete inhibition at 
any of the concentrations. The trend towards some inhibition at concentrations >20 µΜ 
suggests an effect of silver alone. 
 
 
Figure 20. Effect of (A) pleurain R1 alone and (B) [Ag(I)pleurain R1] on the viability of E. coli 
Error bars represent SEM (A) n=9 and (B) n=9 
 
6.5.5. Tigerinin 1 
 
 
Based on the reported MIC value of Tigerinin 1 against E. coli (~30 µM) experimental 
concentrations were selected around this value. Since no MIC has been reported 
against P. aeruginosa, the peptide is tested to a maximum concentration of 250 µM.  The 
results obtained show that Tigerinin 1 is very effective in inhibiting the growth of P. 
aeruginosa (Figure 21A). The peptide showed complete inhibition at a concentration of 
100 µM. The low variability in this experiment suggests 100 µM can be selected as the MIC 
value for Tigerinin 1. The addition of Ag(I) did not show any significant increase in the 
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inhibitory concentration of the peptide or Ag(I). The peptide-metal complex exhibited only 
55% inhibition at 60 µM concentration. The complex strongly suggests an antagonistic 
response as silver alone has the MIC between 30-60 µM. Unexpectedly, the peptide seems to 
bind to silver preventing it from causing inhibition thus decreasing its antibacterial efficiency.  
 
 
Figure 21  Effect of (A) tigerinin 1 alone and (B) [Ag(I)tigerinin1] on the viability of P. 
aeruginosa Error bars represent SEM (A) n=9 and (B) n=9 
 
Tigerinin 1 showed poor activity against E. coli, with the highest inhibition (40%) at 
300 µM concentration (Figure 22A). Interestingly, unlike the previous peptides, the Peptide-
Ag(I) complex showed an increase in the activity of E. coli as compared to P. aeruginosa. The 
Ag(I)-Tigerinin 1 complex showed complete inhibition at the concentration of 40 µM, however 
there is no significant difference between the 30 µM and 40 µM concentrations suggesting a 
MIC in this range. Given the MIC of Ag(I) alone ranges between 30 – 125 µM against E. coli 
(Figure 14B) it cannot be discounted that the inhibition observed here is due only to silver.  
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Figure 22 Effect of (A) tigerinin 1 alone and (B) [Ag(I)tigerinin1] on the viability of E. coli 
Error bars represent SEM (A) n=9 and (B) n=9 
 
6.5.6. Substance P 
 
 
Literature suggests that Substance P has no antimicrobial activity against P. aeruginosa and, 
against the NCTC 8196 strain of E. coli, has a MIC of ~15 µM (135). The experimental values 
were selected based on the reported data. Since no MIC has been reported against P. 
aeruginosa, the peptide is tested for the maximum concentration of 350 µM.   
Substance P showed low to moderate activity against P. aeruginosa (Figure 23A) The peptide 
shows less than 40% inhibition at the highest 300 µM concentrations and given the variability 
it is not likely that Substance P has any affect upon P. aeru. Upon the addition of silver, the 
activity of the peptide significantly improved. Interestingly, and unexpectedly, the graph 
obtained showed a similar response as Substance P alone, with all the peptide having a similar 
percentage inhibition at all tested concentrations. The MIC is difficult to be determined because 
concentrations lower than 10 µΜ were not tested. Nevertheless, this result suggests 
a synergistic response by the Peptide-Ag(I) complex against P. aeruginosa.  
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Figure 23 Effect of (A) Substance P alone and (B) [Ag(I)Substance P] on the viability of P. 
aeruginosa Error bars represent SEM (A) n=9 and (B) n=9 
 
Substance P was more active against E. coli causing 60 % inhibition at 200 µM concentration 
(Figure 24A). Similar to Pleurain R1 against E. coli, the peptide did not cause a dose 
dependent increase in inhibition and a MIC cannot be determined from this data. On the 
other hand, the peptide-metal complex shows less effective response against E. coli. Complete 
inhibition is obtained at 100 µM concentration which is within the range of the MIC of 
silver alone against E. coli.  
 
 
Figure 24 Effect of (A) Substance P alone and (B) [Ag(I)Substance P] on the viability of E. coli. 
Error bars represent SEM (A) n=9 and (B) n=9 
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6.5.7. Mutated Substance P (M1SP) 
 
 
The antibacterial activity of (M1) Substance P was tested independently and along with Ag(I) 
in equal concentrations against P. aeruginosa and E. coli. Since no MIC has been reported 
against P. aeruginosa or E. coli, the peptide is tested for the maximum concentration 
of 200 µM and 350 µM respectively.  
 
M1SP reached 50% inhibition at ~125 µΜ and ~100% inhibition at 150 µM concentration 
against P. aeruginosa (Figure 25). The concentration range was not narrowed to determine an 
accurate MIC but is predicted to be near 150 µΜ. On the addition of silver, the antibacterial 
activity was significantly improved. It can be observed that the peptide has over 100% 
inhibition at 10 µM concentration. Although concentrations lower than 10 µΜ were not tested 
it can be reasonably suggested that the MIC is lower than 10 µM, but for this experiment the 
MIC is taken as 10 µΜ. On comparing the individual MICs of the peptide and silver 
independently versus the metal-peptide complex, a synergistic response is observed. The MIC 
of Ag(I) and M1SP is improved at least 3 fold and 15 fold respectively.   
  
 
Figure 25 Effect of (A) M1Substance P alone and (B) [Ag(I)M1SP] on the viability of P. 
aeruginosa. Error bars represent SEM (A) n=6 and (B) n=3 
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Against E. coli, M1SP was less effective in comparison to P. aeruginosa with highest 60% 
percentage inhibition at 350 µM concentration (Figure 26A). The large variability in the error 
bars suggest that the MIC is achieved at 350 µM or higher. The addition of Ag(I) resulted in 
an improvement in the activity of the peptide (Figure 26B). Considering the variability, it is 
reasonable to suggest the MIC for the complex is between 16.5-27.5 µM. Accordingly, the 
complex shows a mild synergistic response because the MIC of Ag(I) is improved from >30µΜ 
and M1SP is improved at least 12 fold.  
 
 
Figure 26 Effect of (A) M1Substance P alone and (B) [Ag(I)M1Substance P] on the viability of 
E. coli. Error bars represent SEM (A) n=3 and (B) n=9 
  
Discussion: 
The percentage inhibitory results show that silver was effective against both gram-negative 
bacteria, however it appears to be more effective against P. aeruginosa than E. coli. Based on 
the earlier predictions, Latarcin 3b and M1SP were the two peptides that in presence of silver 
showed highest antibacterial activity against both the bacteria. Tigerinin 1 showed an 
antagonistic result against P. aeruginosa in presence of silver. Tigerinin 1 alone was able to 
achieve complete inhibition at 100 µM however in the presence of equimolar silver it showed 
only 50% inhibition at 60 µM concentration. As noted previously, the known presence of a 
disulphide bond in Tigerinin 1 explains the lack of silver binding observed in the NMR 
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experiments, but the antagonistic effect is difficult to explain. Possibly, silver binding occurs 
because the peptide is reduced in the media, and then the complex remains in the media. It is 
not unreasonable to speculate that the structure of the metallo-peptide does not permit 
interaction with the bacterial membrane. Due to the antagonistic effect Tigerinin 1 was not 
studied further. Similarly, NKB was dropped due to poor activity against E. coli. Against E. 
coli, the presence of silver had no effect on the activity of the peptide as the MIC of Ag(I)NKB 
was at least 5 folds higher than that of silver alone thus indicating antagonistic effect. Pleurain 
R1, despite the disulphide bond formation, showed an improved antibacterial activity in 
presence of silver against both the bacteria. In comparison to tigerinin 1, pleurain r1 showed a 
contrasting effect despite the presence of the disulphide bonds between the two cysteines. It 
can be suggested that the improved activity of pleurain r1 on binding with silver is based on 
the placement of the two cysteines on its sequence. The two cysteines being 11 amino acids 
apart and with a methionine present between the two they are likely to bind silver in the nutrient 
media. With no reports confirming a loop formation in pleurain r1 makes them probable of 
showing higher antimicrobial activity in the presence of silver. Thus, it was studied for time-
kill analysis. Similarly, SP was effective against both the bacteria. However, it is interesting to 
see the remarkable difference between the antibacterial activity of Substance P and M1SP. The 
addition of single methionine has greatly improved the activity of Substance P even in the 
absence of silver. In the presence of silver both the peptides showed enhanced activity. 
However, M1SP in contrast to SP showed a synergistic action against E. coli. This difference 
in the antibacterial activity strongly suggests that any change in length, charge or the molecular 
weight has a clear effect on the antimicrobial activity of the peptide.  
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Table 5 MIC values of silver, peptides and Peptides + Ag against P. aeruginosa and E. coli 
Peptide name MIC against P. aeruginosa MIC against E. coli 
Peptide Peptide + Ag Peptide Peptide + Ag 
Silver 30 - 60 µM - 30 – 125 µM - 
NKB >300 µM 2.35 µM – 4.5µM >300 µM ≥300 µM 
Latarcin 3b >60 µM 5 µM > 70 µM ≥ 17.5 µM 
Pleurain R1 >250 µM 15 µM- 20 µM >300 µM > 40 µM 
Tigerinin 1 100 µM > 60 µM (50%) >300 µM 30 µM 
Substance P > 350 µM <10 µM >200 µM 100 µM 
M1 Substance P 150 µM <10 µM >350 µM 22 µM 
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 Time Kill Curve Analysis 
 
To further study the antibacterial effect of the peptides and the peptide-silver complexes dose 
curve analysis was performed. Time-kill curve experiments are considered to be more accurate 
than the percentage inhibition experiment (142). The bacteria were treated with different 
concentrations of the peptide and the Peptide-Ag(I) complex and absorbance readings (595 nm) 
were taken at 0 min, 30 min and then at every one hour over a period of 16 hours. As noted in 
the methodology, the absorbance at 595 nm can be correlated to the bacterial growth. 
 
6.6.1. Latarcin 3b 
 
 
Latarcin 3b was first tested against P. aeruginosa against which it showed a peculiar effect. 
Latarcin 3b had a slow response against the bacteria as the bacteria first shows an exponential 
growth but starts to decline after a few hours of exposure (Figure 27). The higher peptide 
concentrations showed an earlier decline compared to low concentrations. For example, 30 µM 
concentration shows a decline in the growth after 10 hours whereas at 55 µM concentration the 
decline starts after 7 hours and approaches complete inhibition by ~14 hrs. The antibacterial 
effect of Latarcin 3b became clearer after this experiment with an MIC value of 55 µM. Next, 
P. aeruginosa was treated with different concentrations (0-25 µΜ) of the Latarcin 3b-Ag(I) 
complex. Unlike Latarcin 3b by itself, the combination showed immediate effect on the 
bacteria. The complex showed complete inhibition at 5 and 10 µM concentrations. Hence, this 
supports the combined MIC of ~5 µM suggested by the previous inhibition assays. Further, the 
increase in the bacterial growth at lower concentrations was proportional to the decrease in the 
concentration of the Peptide-Ag(I) complex. The results confirm the predicted synergy against 
P. aeruginosa since the individual MIC of both Ag(I) and Latarcin 3b are more than 5 µM. 
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Next, Latarcin 3b was tested against E. coli. Latarcin 3b at the highest concentration of 60 µM 
(Figure 27C) as able to inhibit the bacterial growth up to first 5 hours thus, being the MIC. A 
delayed bacterial growth was observed at all the other concentrations. When the latarcin-Ag(I) 
complex was tested there was a decrease in the bacterial growth with the increase in the 
Peptide-Ag(I) concentration. The complex showed complete inhibition at 17.5 µM, 15 µM and 
12.5 µM up to 13 hrs, 12 hrs and 4 hrs respectively. This data suggests the MIC is ~ 12.5 µM. 
Taken together with the previous inhibition assays, the data highlights the significant 
improvement in activity of the peptide in the presence of Ag(I). Overall, these experiments 
confirm the suggested synergy between Latarcin 3b and silver against both P. aeruginosa and 
E. coli. 
 
Figure 27 Time- kill curves for Latarcin 3b against (A) P. aeruginosa and (C) E. coli, and the 
Latarcin 3b-Ag(I) complex against (B) P. aeruginosa and (D) E. coli. Concentrations tested 
are noted at the top of each graph. Error bars represent SEM, A) n = 9, B) n = 9,  C) n = 6, D) 
n = 6.  
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6.6.2. Pleurain R1 
 
 
Pleurain R1 was first independently tested in the P. aeruginosa time-kill assays at 
concentrations up to 250 µM (Figure 28A). Pleurain R1 showed a similar effect as observed in 
the percentage inhibition graphs. Within the variability in the experiment, all the test 
concentrations (100-250 µM) exhibit a similar effect on bacterial growth. However, pleurain 
R1 appeared to show its effect only after 5 hours of exposure to the bacteria, until then there 
was no difference in the bacterial growth. No conclusive MIC could be obtained from this data. 
Next, the combinatorial effect of equimolar concentrations of Pleurain R1 and silver was tested 
against P. aeruginosa. The results (Figure 28B) show that Pleurain R1 + Ag(I) containing 
samples have growth rates similar to cells alone, but inhibition becomes apparent after two 
hours of exposure. After two hours of incubation, complete inhibition was observed up to the 
minimum concentration of 15 µM. At the lowest test concentration of 10 µM the bacteria begin 
show an exponential growth. From this experiment the MIC is estimated to be around 10 µΜ. 
This result is lower than what was observed in the inhibition assays (15 µM < MIC < 20 µM). 
Although the MIC is largely driven by the metal (30 µΜ < MIC < 60 µΜ) the results here 
suggests the complex is slightly more effective than Ag(I) alone. This is difficult to reconcile 
with the NMR and UV/Vis data which show no binding unless the peptide is reduced. However, 
the binding experiments were conducted in aqueous buffer, or just water, and the 
inhibition/time kill assays were conducted in growth media. It is possible that the peptide 
undergoes some reduction in the media which allows some Ag(I)-binding.  
 
Next, Pleurain R1 was tested against E. coli. The results for apo-pleurain R1 (0-250 µΜ) are 
shown in Figure 28C. The considerable variability observed in this experiment is difficult to 
explain, and it appears that there is no real difference between treated samples and cells alone. 
The addition of Ag(I) resulted in a slower growth in comparison to the growth by Pleurain R1 
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alone. The pleurain R1- Ag(I) complex showed complete inhibition at 40 µM, 30 µM and 20 
µM up to 7 hrs but, after 7 hours E. coli began to grow noticeably. Similar behaviour was 
observed upon treatment with 15 µM Peptide-Ag(I) complex where the cells began to grow 
again after 4 hours (Figure 28D). Thus, the MIC of the complex is ~ 15 µM. This result is 
similar to the trends observed in the inhibition assay and suggests most of the killing is 
mediated by silver alone with a marginal effect associated with the addition of the peptide. 
 
Figure 28 Time- kill curves for pleurain R1 against (A) P. aeruginosa and (C) E. coli, and the 
Pleurain R1-Ag(I) complex against (B) P. aeruginosa and (D) E. coli. Concentrations tested 
are noted at the top of each graph. Error bars represent SEM, A) n = 9, B) n = 3, C) n = 9 D) n 
= 9. 
 
6.6.3. Substance P 
 
 
Substance P was first tested against P. aeru.  The results showed a similar response against the 
bacteria at all the test concentrations, and there is a small inhibition when compared to cells 
alone. This is similar to the results obtained in the inhibition assays (Figure 23). Substance P 
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in the presence of equal concentrations of silver showed a remarkable increase in the 
antibacterial activity with complete inhibition at all the test concentrations, with the lowest 
being 10 µM. Hence, 10 µM in the combined MIC of Ag(I)Substance P against P. aeruginosa, 
confirming the synergistic effect predicted by the inhibition assays. 
Next, Substance P was then tested against E. coli. Substance P showed better activity against 
E. coli as compared to P. aeruginosa, however, like P. aeruginosa the peptide showed a similar 
constant inhibition at all the test concentrations (0-200 µΜ). The results are broadly similar to 
the inhibition assay (Figure 24) which showed a ~60% inhibition at the concentrations used 
here. To test the combinatorial effect, Substance P was tested along with silver in equal 
concentration against E. coli. The results show decrease in the bacterial growth with the 
increase in the Peptide-Ag(I) concentration. The complex showed complete inhibition at 200 
µM followed by complete inhibition at 150 µM up to 7 hrs. At 100 µM negligible growth can 
be observed throughout the test duration (Figure 29C). Thus 100 µM is the combined MIC of 
substance P + Ag against E. coli which is identical to that suggested by the inhibition assays. 
As noted in the inhibition assays, the MIC for silver alone against E. coli (30-125 µΜ) 
suggesting the effect here is due only to silver. 
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Figure 29 Time- kill curves for Substance P against (A) P. aeruginosa and (C) E. coli, and the 
Substance P-Ag(I) complex against (B) P. aeruginosa and (D) E. coli. Concentrations tested 
are noted at the top of each graph. Error bars represent SEM, A) n = 6, B) n = 3, C) n = 3, D) 
n= 3 
 
6.6.4. M1 Substance P 
 
 
M1SP was the fourth peptide to be tested in the time kill assays. The test concentrations were 
based on the previous percentage inhibition experiment.M1SP was first independently tested at 
the concentrations up to 250 µM against P. aeru. M1SP showed a similar effect as observed in 
the percentage inhibition graphs. The high antibacterial activity of M1SP against P. aeruginosa 
is evident from the graph. M1SP showed complete inhibition against P. aeruginosa at all the 
test concentrations, however, the bacteria showed growth after 9 hours upon treatment with 
125 µM M1SP. This suggests 125 µM is the MIC of M1SP against E. coli, which is consistent 
with the result from the inhibition assay (130 µΜ). Next, the addition of silver to the peptide 
resulted in complete inhibition within the first 30 min at the lowest concentration of 10 µM. 
Again, this is entirely consistent with the inhibition assays and makes 10 µM the MIC of the 
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metal complex against P. aeruginosa and further confirming the synergistic effect (Figure 
30B). However, as noted previously lower concentrations were not tested.  
  
Next, the effect of M1SP was tested against E. coli. The graph shows a clear dose dependent 
reduction in bacterial growth. However, complete inhibition can be observed for up to 8 hours 
at 350 µM, confirming it to be the MIC (Figure 30C). To test the combinatorial effect, M1SP 
was tested along with silver in equal concentration against E. coli. The results show similar 
trend as exhibited by M1SP alone. There was a decrease in bacterial growth with an increase in 
the Peptide-Ag(I)concentration. There was no growth at the highest concentration of 27.5 µM 
concentration. All the other test concentration showed complete inhibition up to a certain 
number of hours with the lowest test concentration of 5.5 µM showing complete inhibition till 
4 hours. The complexes MIC can be taken as 5.5 µM concentration which is lower than that 
suggested by the inhibition assays (22 µΜ). Thus, the experiment suggests a synergy between 
M1SP and silver against E. coli. 
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Figure 30 Time- kill curves for M1Substance P against (A) P. aeruginosa and (C) E. coli, and 
the M1Substance P-Ag(I) complex against (B) P. aeruginosa and (D) E. coli. Concentrations 
tested are noted at the top of each graph. Error bars represent SEM, A) n = 6, B) n = 3, C) n = 
6, D) n= 3 
 
Discussion: 
The time kill assays are a more accurate analysis of the MIC values. All four peptides selected 
after the inhibition assays were shown to exhibit better antibacterial activity in the presence of 
silver than either individual component (Table 6). The peptides that were clearly shown to bind 
Ag(I) when assessed by NMR (Latarcin 3b andM1SP) appear to be more effective antibacterial 
agents when in a Ag(I) complex when compared to pleurain R1 and substance P.  As noted 
previously, it is not clear why pleurain R1 shows an enhancement when in the presence of 
Ag(I), given the lack of binding by NMR, but it is possible some reduction of the peptide occurs 
in the media. Reduction may occur either in the bulk media, or may occur after the peptide 
Navya Kapoor | 95  
 
interacts with the bacterial membrane. Based on the results of the time kill experiment Latarcin 
3b and M1SP were chosen for further study.   
 
Table 6 MIC values of peptides and peptides + Ag against P. aeruginosa and E. coli based on 
time-kill analysis 
Peptide name MIC against P. aeruginosa  MIC against E. coli  
Peptide Peptide +Ag(I) Peptide Peptide + Ag(I) 
Latarcin 3b 55 µM 5 µM 60 µM 12.5 µM 
Pleurain R1 >250 µM 10 µM >300 µM 15 µM 
Substance P > 350 µM 10 µM >200 µM 100 µM 
M1 S P 125 µM 10 µM 350 µM 5.5 µM 
 
The peptides Latarcin 3b and M1Sp were calculated for their FIC index to quantitatively 
determine synergy. The Table 7 and Table 8 show the fractional inhibitory calculation for 
Latarcin 3b and M1SP respectively. Based on the calculated values it can be confirmed that 
Latarcin 3b and M1SP show a synergistic effect against both gram negative bacteria. 
 
Table 7 FIC of Latarcin 3b in combination with against P. aeruginosa and E. coli 
 MIC 
combination/ 
Latarcin 3b 
alone  
MIC combination/ 
Ag(I) alone 
FIC (Latarcin 
3b) + FIC 
(Ag(I)) 
Combinatorial 
effect (≤0.5= 
Synergistic) 
P. aeruginosa  5 µM / 55 µM 5 µM / 60 µM 0.09 + 0.08 0.17, 
Synergistic 
E. coli 12.5 µM / 60 µM 12.5 µM / 125 µM 0.2 + 0.1 0.3, Synergistic 
 
Navya Kapoor | 96  
 
Table 8 FIC of M1SP in combination with against P. aeruginosa and E. coli 
 MIC 
combination/ 
M1SP alone 
MIC 
combination/ 
Ag(I) alone 
FIC (M1SP) + 
FIC (Ag(I)) 
Combinatorial 
effect (≤0.5= 
Synergistic) 
P. aeruginosa  10 µm/ 125 µm 5 µm/ 60 µm 0.08 + 0.08 0.16, 
Synergistic 
E. coli 5.5 µm/ 350 µm 12.5 µM / 125 
µM 
0.015 + 0.1 0.115, 
Synergistic 
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 Subcellular Fractionation of P. aeruginosa 
 
 
The underlying reason for the synergistic activity of Ag(I)-bound latarcin 3b and M1SP is not 
clear but is likely dependent on where in the cell the peptide and silver acts. To begin to 
investigate the mechanism of action of the metallo-peptide complex against the bacteria a 
subcellular fractionation was performed and the location of silver was determined. 
 
P. aeruginosa was first treated with the metallo-peptides and then fractioned into cytoplasmic, 
periplasmic and crude membrane fractions. Each fraction was then tested for its silver and 
protein concentrations using atomic absorption spectroscopy (AAS) and the BCA assay 
respectively. The concentration of silver in each fraction was normalized using the protein 
concentration as a proxy for the number of cells investigated. P. aeruginosa was tested with 
silver alone at concentrations of 10 µM, 30 µM and at the MIC concentration of 60 µM. The 
samples were then fractionated using the cellular sub fractionation protocol as described in the 
methodology. The analysis showed that silver was largely observed in the periplasmic region 
with a negligible amount in the membrane region of the cell fraction (Figure 31). Silver was 
able to be detected only in the sample containing 60 µM of silver. It is possible that at lower 
concentrations of silver, the bacteria are able to limit uptake which allows the growth observed 
in the inhibition assays and any metal that was taken up was below the detection limit of the 
AAS. Likely, the silver has remained in the media and was discarded as per the protocol. 
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Figure 31 Concentration of silver in specific cell fractions of P. aeruginosa after treatment with 
0.01 mM, 0.03 mM and 0.06 mM silver 
 
To compare the effect of silver with peptide bound silver the bacteria was then treated with 
Latarcin3b-Ag(I) at 5 µM and M1SP-Ag(I) at 8µM which is close to their MIC concentrations. 
These results showed detectable silver only in the crude membrane fraction (Figure 32). 
 
 
Figure 32 Concentration of silver/protein in specific cell fractions after treatment with Latarcin 
3b- Ag(I), M1SP-Ag(I) and silver alone. 
 
From these results the peptide bound silver had a different site of action as compared to silver 
alone. Since silver alone was in the highest concentration in the periplasm, the presence of 
peptide localises the silver to the membrane region. As described in the introduction the impact 
of intracellular silver is associated with the ability of the metal to bind to enzymes and inhibit 
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function.  The results here suggest that coordination of silver to the peptide traps the metal at 
the membrane, presumably in complex with the peptide. It is reasonable to predict that the 
mechanism of action that underlies the improved activity of the complex compared to the 
peptide or the metal alone is related to membrane disruption and suggests that the presence of 
silver is able to enhance the membrane lytic-activity of the peptide. The conformation of 
latarcin 3b and M1SP is constrained by silver coordination to the methionine amino acids which 
induces the formation of a cyclic peptide. This structure appears to be more effective that the 
peptide alone in disrupting the membrane structure.  
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7. Summary 
 
 
Antimicrobial resistance has become a global issue, there are various international 
organizations alarmed about the approaching danger. One of the strategies to survive this 
situation is to develop new and target-specific antibacterial agents. Acknowledging the need 
for novel antibacterial agents the primary objective of the project was to explore the potential 
of silver-binding peptides to serve as antibacterial agents. 
 
AMPs are produced as an innate response by multicellular organisms to battle pathogenic 
microorganisms and are considered to be the first line of defense. AMPs have a broad 
mechanism of action with multiple targets within the cell due their unique structure and 
amphipathic nature facilitate their direct interaction with the intracellular and extracellular 
targets. AMPs can cause membrane barrier disruption, intracellular target uptake and 
inhibition, negatively alter cytoplasmic membrane permeability, prevent protein synthesis, cell 
division, cell wall biosynthesis and macromolecular biosynthesis as a part of its action 
mechanism. Due to their various target mechanism and multiple action it causes a bactericidal 
effect on the bacteria. Since they have a bactericidal action, the chances of bacterial resistance 
is reduced, making AMPs a potential drug model. 
 
Metals have been used as antibacterial for centuries to purify water and food. Although they 
have been continuously used till date, these metals are still effective and the bacteria has not 
developed resistance against them. Silver is one such metal that has been widely reported in 
literature to have antimicrobial property. Silver is known to have a broad action mechanism, it 
interacts with the amino acids in the DNA and disrupt it, it also prevents the transcription of 
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various proteins necessary for cell survival. However, silver cannot be directly used as a drug 
because of its high toxicity.  
 
In order to overcome the bacterial resistance and the problem of silver toxicity various peptides 
were tested independently and in combination with silver. The project was based on the 
hypothesis that complexing the metal and peptides would result in a broader and complex 
mechanism of action. A combination of two, highly effective antibacterial agents could show 
synergistic effect to lower the MIC, which would help overcoming the problem of toxicity and 
the killing time would also be considerably reduced. 
 
Some of antimicrobial peptides tested here showed antibacterial effect against E. coli and P. 
aeruginosa, however in the presence of silver their activity greatly improved suggesting that 
combining the two antibacterial agents resulted in a synergistic response against the bacteria. 
The prediction of the antimicrobial potential of the Apo-peptides based on their physiochemical 
property supported the experimental results. 
 
The effect of high net charge, high amphipathicity and high protein binding potential on the 
antimicrobial activity of a peptide was justified by the peptide Latarcin 3b. Latarcin 3b 
independently showed high effectiveness against both the gram-negative bacteria and was 
active at low concentrations. Latarcin 3b showed clear binding of silver as observed in the 
NMR and UV-Vis data. The binding of silver with Latarcin improved its independent activity 
12-fold. The latarcin 3b-Ag(I) complex showed a synergistic effect. Based on the cell 
fractionation experiment it can be said that the binding of the peptide to the silver facilitates its 
localisation in the cell membrane as opposed to the periplasm. The synergism may be related 
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to improved membrane-lytic activity, which may be due to the structure adopted by the latarcin 
3b-Ag(I) complex.  
 
The peptide M1 SP was inspired by the metal binding ability of NKB which has two methionine 
and each end of the peptide. A peptide modified from a known antimicrobial peptide, Substance 
P, with metal binding features of another neuropeptide, NKB, was expected to have great 
potential as an antibacterial peptide. The antibacterial activity of M1SP was noticeably different 
from that of Substance P. This highlights the impact of molecular weight, aliphatic index and 
instability index on the antimicrobial activity of the peptide. The improved thermos ability and 
increased half-life resulted in higher activity of M1SP. In the presence of silver, the independent 
activity of M1SP was increased by over 60 fold against E. coli and the peptide-Ag(I) complex 
showed synergy against both the bacteria. Similar to Latarcin 3b, M1SP showed silver located 
in the crude membrane. The improved combined activity and the presence of silver suggests 
the mechanism of M1SP to be membrane based, similarly to latarcin 3b-Ag (I). 
 
Both the peptides independently and in combination with silver showed high antimicrobial 
activity at very low concentrations. It can be suggested that the combination of the two 
antibacterial have enhanced the activity due to the multiple modes of actions of both the peptide 
and metal. The low concentrations of silver can overcome its problem of toxicity. This peptide-
metal complex holds potential as a novel antibacterial agent, which with more research and 
testing, may have potential as therapeutic agent.  
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VII. Appendix 1 
 
Table 1 Shortlisted peptides based on predicted silver binding ability 
Name Sequence Length Charge Hydrophobicity 
Substance P RPKPQQFFGLM 11 3 36% 
Brevinin-1SPb FLPIIAGMAAKVICAITKKC 20 
 
3 
 
70% 
Tigerinin-1 FCTMIPIPRCY 11 1 54% 
Pleurain-R1 CVHWMTNTARTACIAP 16 1 56% 
Japonicin-1Npb FVLPLVMCKILRKC 14 
 
3 71% 
Ranalexin-1Ca FLGGLMKAFPALICAVTKKC 20 3 65% 
pCM19 CLRIGMRGRELMGGIGKTM 19 3 42% 
Latarcin 3b  SWASMAKKLKEYMEKLKQRA 20 5 40% 
Brevinin-1SPd FFPIIAGMAAKVICAITKKC 20 3 
 
70% 
Ranalexin-1Cb FLGGLMKAFPAIICAVTKKC 20 3 65% 
Ranalexin-1G FLGGLMKIIPAAFCAVTKKC 20 3 
 
65% 
Ranalexin FLGGLIKIVPAMICAVTKKC 20 3 65% 
Hepcidin CRFCCRCCPRMRGCGLCCRF 20 5 60% 
Japonicin-1Npa FLLFPLMCKIQGKC 14 2 64% 
Dybowskin-2 FLIGMTQGLICLITRKC 17 2 
 
58% 
Dybowskin-1 FLIGMTHGLICLISRKC 17 2 
 
58% 
Shuchin 5 KAYSMPRCKYLFRAVLCWL 19 5 57% 
Odorranain-G1 FMPILSCSRFKRC 13 3 53% 
Shuchin 3 KAYSMPRCKGGFRAVMCWL 19 5 52% 
Shuchin 4 KAYSTPRCKGLFRALMCWL 19 5 52% 
Shuchin 1 NALSMPRNKCNRALMCFG 18 3 50% 
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limnonectin-1Fb SFHVFPPWMCKSLKKC 16 3 50% 
Mp_mastoparan 
MP 
INWLKLGKKMMSAL 14 4 57% 
HYL GIMSSLMKKLAAHIAK 16 4 56% 
Melectin GFLSILKKVLPKVMAHMK 18 5 55% 
Temporin-MS1 FLTGLIGGLMKALGK 15 2 53% 
VESP-VB1 FMPIIGRLMSGSL 13 1 53% 
Maximin S4 RSNKGFNFMVDMIQALSK 18 2 44% 
Phylloxin-B1  GWMSKIASGIGTFLSGMQQ 19 1 42% 
Macropin 2 GTGLPMSERRKIMLMMR 17 4 41% 
Latarcin 3a SWKSMAKKLKEYMEKLKQRA 20 6 35% 
Tigerinin-3 RVCYAIPLPICY 12 1 58% 
RTD-2 GVCRCLCRRGVCRCLCRR 18 6 55% 
BTD-2 RCVCRRGVCRCVCRRGVC 18 6 55% 
PhTD1 RCVCRRGVCRCVCTRGFC 18 5 55% 
BTD-7  RCVCTRGFCRCFCRRGVC 18 5 55% 
BTD-1 RCVCTRGFCRCVCRRGVC 18 5 55% 
RTD-1 GFCRCLCRRGVCRCICTR 18 5 55% 
PhTD3 RCVCTRGFCRCVCTRGFC 18 4 55% 
BTD-3 RCVCTRGFCRCVCTRGFC 18 4 55% 
RTD-3 GFCRCICTRGFCRCICTR 18 4 55% 
Cerecidin A7 TTPLCVGVIIGITASIKICK 20 2 55% 
Piceain 1 KSLRPRCWIKIKFRCKSLKF 20 8 45% 
Polyphemusin II RRWCFRVCYKGFCYRKCR 18 8 44% 
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Table 2 Peptides predicted for potential antimicrobial properties 
 
 
 
 
Name Sequence Hydropho
bic ratio 
Net 
charge 
Protein 
binding 
potential 
(kcal/mol
) 
Structure 
prediction  
NKB 
(zebrafish) 
EMHPDEFVGLM 45% -3 0.85  Alpha 
helices 
NKB 
M2P,D4T 
DPMTDFFVGLM 54% -2 -0.04 Alpha 
helices 
NKB F6C DMHDFCVGLM 60% -2 0.32 Alpha 
helices 
NKB V7C DMHDFFCGLM 60% -2 0.43 Alpha 
helices 
NKB G8C DMHDFFVCLM 70% -2 0.12 Alpha 
helices 
NKB 
D1P,H3T 
PMTDFFVGLM 60% -1 -0.92 Alpha 
helices 
ATCUN 
peptide 
LHSALPF 57% 0 -0.93 No helix 
ATCUN 
peptide 
AYHSALPF 50% 0 -0.41 No helix 
ATCUN 
peptide 
GYHSGLPF 25% 0 -0.19 No helix 
NKB C11 DMHDFFVGLMC 63% 
 
-2 0.02 Alpha 
helices 
Prion 
Protein 
(91-126) 
QWNKPSKPKTNMKHMAGA
AAGAVVGGLGGYMLGSA 
40% 4 0.29 Alpha 
helices 
NKB L9C DMHDFFVGCM 60% -2 0.51 Alpha 
helices 
Substance 
P 
MRPKPQQFFGLM 41% 2 1.25 Alpha 
helices 
Neurokinin 
B 
DMHDFFVGLM 54% -2 0.05 Alpha 
helices 
Prion 
protein 
(106-126) 
KTNMKHMAGAAAAGAVVG
GLG 
52% 2 -0.39 Alpha 
helices 
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